| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Hematologic System |
Recent Updates
Recently added Catalysts
Agios Pharmaceuticals, Inc.$41.23
-1.56 (-3.65%)
C 53Pipeline Score Overvalued Pharma · Commercial
Market Cap
1.58 B
EPS
-7.25
P/E Ratio
-3.66 $
Value Trade
18.63 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
20.75 M
R&D Expenses
81.15 M
Operating CF
-118.92 M
Total Assets
1.18 B
Total Liabilities
75.88 M
Equity
1.11 B
D/E Ratio
12,345
-1.26 %
Week
6.23 %
1 Month
-1.12 %
3 Month
14.11 %
6 Month
-50.85 %
5 Year
-2.97 %
All Time
Cash Data
Cash Position
737.04 M
Monthly Burn
39.64 M
Runway
16.4 mo
Burn Trend
SEC Filing
Apr 29, 2026
Overview
Volume
1.13 M
52 Week Range
22.24 - 46
% held by Insiders
6.38 %
% held by Institutions
106.49 %
Enterprise Value
875.30 M
Total Shares
59.46 M
Short %
12.11 %
Float Shares
55.77 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Agios Pharmaceuticals, Inc.
1079Total events
10Upcoming
225Tier-1 (high impact)
2014 – 2028Coverage
Upcoming catalysts 10
Dec 2026
T1FDA Approval
Receive regulatory approvals globally for mitapivat in three initial indications
TBD
T2EU MAA Submission
Marketing application for PYRUKYND in thalassemia under review by European Commission
TBD
T1EU Approval
Marketing application for mitapivat in thalassemia under review by European Commission
Event history 1069
Q3 2026
◆FDA Filing AcceptedMitapivatApprovedRegulatory Filing
Expected FDA filing acceptance and review timeline for mitapivat sNDA
sickle cell diseasesource ↗
Jun 13, 2026
▲Oral PresentationMitapivatApprovedPresentation
Presentation of RISE UP Phase 3 results at EHA 2026 Plenary Session
sickle cell diseasesource ↗
Jun 13, 2026
Jun 13, 2026
◆Poster PresentationMitapivatApprovedPresentation
Poster on metabolic profile of Diamond-Blackfan anemia syndrome erythroid progenitors
Diamond-Blackfan anemia syndromesource ↗
Jun 13, 2026
Jun 13, 2026
◆Full ResultsMitapivatApprovedClinical Data
Detailed efficacy and safety data from RISE UP Phase 3 trial presented at EHA 2026
sickle cell diseasesource ↗
Jun 13, 2026
◆Long Term DataMitapivatApprovedClinical Data
Long-term data from ENERGIZE open-label extension showing durability up to 127 weeks
non-transfusion-dependent alpha- or beta-thalassemiasource ↗
Jun 12, 2026
◆Poster PresentationMitapivatApprovedPresentation
Poster on subgroup analysis of ENERGIZE in patients with baseline hemoglobin ≥9.5 g/dL
non-transfusion-dependent alpha- or beta-thalassemiasource ↗
Jun 12, 2026
◆Subgroup AnalysisMitapivatApprovedClinical Data
Subgroup analysis of ENERGIZE in patients with baseline hemoglobin ≥9.5 g/dL
non-transfusion-dependent alpha- or beta-thalassemiasource ↗
Jun 11, 2026
◆Oral PresentationMitapivatApprovedPresentation
Oral presentation of SATISFY Phase 2 trial results at EHA 2026
hereditary spherocytosis, hereditary xerocytosis, congenital dyserythropoietic anemia type IIsource ↗
Jun 11, 2026
◆Long Term DataMitapivatApprovedClinical Data
56-week follow-up results from SATISFY study on iron burden and spleen size
hereditary spherocytosis, hereditary xerocytosis, congenital dyserythropoietic anemia type IIsource ↗
Jun 1, 2026
▲Partnership / LicensecevidoplenibCorporate
Agios enters exclusive global license agreement with Oscotec for cevidoplenib
immune thrombocytopeniasource ↗
Drug Pipeline Intelligence
C53
Pipeline Score $974M
Pipeline ValueOvervalued
Valuation Signal12
Drugs Scored0.6x
rNPV / MCap Top 81%
Micro Cap (rank 174 of 911)
Percentile RankAgios Pharmaceuticals, Inc. carries a moderate pipeline score (53/100), with $2.5B risk-adjusted pipeline value, led by Mitapivat in Sickle Cell Disease (Phase 3), across $69B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mitapivat Small molecule | Transfusion-dependent Alpha-Thalassemia | Phase 3 | NCT04770779 | 85% | $722M | ACTIVE NOT_RECRUITING | 312 | SLOW | B (73) | Jun 1, 2029 | LOW_RISK | LOW Jun 23, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
mitapivat PriorityAccelerated | sickle cell disease | Phase 3 | 2026-06-13 | significant improvement in hemoglobin response compared with placebo; clinically meaningful reduction in transfusion burden compared with placebo; patients in mitapivat arm who achieved hemoglobin response had clinically meaningful benefits across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes; reduction in the annualized rate of sickle cell pain crises (SCPCs) compared with placebo; no overall difference between mitapivat and placebo for the key secondary endpoint measuring patient-reported fatigue Read More | Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Read More | |
mitapivat PriorityAccelerated | sickle cell disease | Phase 3 | 2026-06-13 | significant improvement in hemoglobin response compared with placebo; clinically meaningful reduction in transfusion burden compared with placebo; patients in mitapivat arm who achieved hemoglobin response had clinically meaningful benefits across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes; reduction in the annualized rate of sickle cell pain crises (SCPCs) compared with placebo; no overall difference between mitapivat and placebo for the key secondary endpoint measuring patient-reported fatigue Read More | Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Read More | |
mitapivat PriorityAccelerated | sickle cell disease | Phase 3 | 2026-06-13 | significant improvement in hemoglobin response compared with placebo; clinically meaningful reduction in transfusion burden compared with placebo; patients in mitapivat arm who achieved hemoglobin response had clinically meaningful benefits across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes; reduction in the annualized rate of sickle cell pain crises (SCPCs) compared with placebo; no overall difference between mitapivat and placebo for the key secondary endpoint measuring patient-reported fatigue Read More | Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AGIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AGIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AGIO▲ +8%on this news
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Agios Pharmaceuticals has presented promising results from the RISE UP Phase 3 trial of mitapivat for sickle cell disease at the EHA 2026 Congress. The trial demonstrated significant improvements in hemoglobin response and a notable reduction in transfusion dependency while remaining well-tolerated by patients. However, despite these positives, the primary endpoint for measuring pain crises did not achieve statistical significance. Overall, the data suggests a strong anti-hemolytic profile for mitapivat, highlighting its potential to enhance the quality of life for patients suffering from this condition.
Read more →AGIOAgios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
Agios Pharmaceuticals has entered an exclusive global license agreement with Oscotec to develop cevidoplenib, a next-generation SYK inhibitor for immune thrombocytopenia (ITP). The agreement allows Agios to diversify its rare hematology portfolio and potentially achieve up to $1 billion in peak U.S. sales. Cevidoplenib aims to improve treatment outcomes for ITP patients, building on Phase 2 trial data that demonstrated durable platelet responses.
Read more →AGIOAgios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
Agios Pharmaceuticals announced that it will not advance tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after its Phase 2b trial failed to meet predefined efficacy thresholds. Although the drug was well tolerated and showed biological activity, it did not demonstrate sufficient clinical benefit. The company remains optimistic about tebapivat's potential in treating sickle cell disease, with further data expected later in 2026.
Read more →AGIOResumen: El socio de Avanzanite Bioscience, Agios anuncia la autorización de PYRUKYND® (mitapivat) en la Unión Europea para adultos con talasemia
Agios has announced the authorization of PYRUKYND® (mitapivat) in the European Union for adults with thalassemia. This marks a significant regulatory achievement for the company and its partner, Avanzanite Bioscience. The approval may enhance treatment options for patients suffering from this condition.
Read more →AGIOAgios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
Agios Pharmaceuticals has received marketing authorization from the European Commission for PYRUKYND (mitapivat), the first medicine approved in the EU for adults with both transfusion-dependent and non-transfusion-dependent thalassemia. This approval is based on positive results from Phase 3 clinical trials, highlighting the drug's potential to improve patient outcomes. Agios will collaborate with Avanzanite Bioscience for distribution in Europe, further expanding access to this important treatment.
Read more →AGIOSamenvatting: Avanzanite Bioscience’s partner Agios maakt de goedkeuring van PYRUKYND® (mitapivat) in de Europese Unie bekend voor volwassenen met thalassemie
Agios has announced the approval of PYRUKYND® (mitapivat) in the European Union for adults with thalassemia. This marks a significant milestone for the company and its partner, Avanzanite Bioscience. The approval is expected to enhance treatment options for patients suffering from this condition.
Read more →AGIORiassunto: Agios, partner di Avanzanite Bioscience, annuncia l'approvazione di PYRUKYND® (mitapivat) nell'Unione europea per gli adulti affetti da talassemia
Agios, in partnership with Avanzanite Bioscience, announced the approval of PYRUKYND® (mitapivat) in the European Union for adults with thalassemia. However, the article provides limited information regarding the implications of this approval or the approval process itself.
Read more →AGIOAgios, partenaire d’Avanzanite Bioscience, annonce l’autorisation de mise sur le marché de PYRUKYND® (mitapivat) dans l’Union européenne pour les adultes atteints de thalassémie
Agios, in partnership with Avanzanite Bioscience, has announced the EU market authorization of PYRUKYND® (mitapivat) for adults suffering from thalassemia. This approval marks a significant advancement in treatment options for patients in the European Union, enhancing accessibility to this important therapy.
Read more →AGIOAgios, Partner von Avanzanite Bioscience, gibt die Zulassung von PYRUKYND® (Mitapivat) in der Europäischen Union für Erwachsene mit Thalassämie bekannt
Agios Pharmaceuticals, in partnership with Avanzanite Bioscience, has announced the approval of PYRUKYND® (Mitapivat) in the European Union for adults with thalassemia. This approval marks a significant milestone for the treatment of this condition. Further details about the implications of this approval were not provided.
Read more →AGIOAvanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Agios has announced the approval of PYRUKYND® (mitapivat) in the European Union for adult patients with thalassaemia. This marks a significant milestone for Agios and its partner Avanzanite Bioscience. The approval is expected to enhance treatment options for patients suffering from this condition.
Read more →AGIOAgios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
Agios Pharmaceuticals has announced that new data on mitapivat will be presented at EHA 2026, highlighting its significant therapeutic impact on multiple rare hemolytic anemias. Key presentations will include results from the RISE UP Phase 3 trial, which reported notable improvements in hemoglobin responses and reduced markers of hemolysis in patients with sickle cell disease. The company also plans to share long-term data showing sustained efficacy across various patient populations. This event marks a key opportunity for Agios to engage with the hematology community regarding advancements in treatment options.
Read more →AGIOAgios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
Agios Pharmaceuticals has submitted a supplemental New Drug Application (sNDA) to the FDA for mitapivat, aiming for accelerated approval in treating sickle cell disease. The submission follows an agreement with the FDA on a confirmatory clinical trial, which will evaluate the drug's effectiveness in reducing transfusion burden. Mitapivat has shown promising results in previous trials, including improved hemoglobin levels and reductions in related complications. The outcomes from this confirmatory trial are crucial for translating accelerated approval into traditional approval.
Read more →AGIO▲ +13.1%on this news
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
Agios Pharmaceuticals reported a strong first quarter for 2026, with net revenues from mitapivat reaching $20.7 million, a significant increase from the previous year. The company successfully launched AQVESME for thalassemia, with 242 prescriptions written. Agios plans to submit a supplemental New Drug Application for mitapivat in sickle cell disease in Q2 2026, marking a key growth opportunity.
Read more →AGIO▲ +13.1%on this newsshared move
Document Agios Reports First Quarter 2026 Financial Results and Provides Business Update Mitapivat (PYRUKYND and AQVESME ) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7
Agios Pharmaceuticals reported its financial results for the first quarter of 2026, highlighting a significant increase in revenue generated by its product mitapivat. The company noted strong early adoption of its new drug AQVESME in thalassemia, with 242 prescriptions written to date. Agios plans to submit a supplemental New Drug Application (sNDA) for mitapivat targeting sickle cell disease in the second quarter of 2026. Despite these positive developments, the company also reported an increase in net losses and rising operational expenses, presenting some financial challenges moving forward.
Read more →AGIOAgios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
Agios Pharmaceuticals, a biopharmaceutical company specializing in rare diseases, announced that it will host a conference call and live webcast on April 29, 2026, at 8:00 a.m. ET to discuss its first quarter 2026 financial results and business highlights. The event will be accessible through the Investors section of Agios' website, where a replay will also be available. The announcement reflects Agios' commitment to keeping investors informed about its operations and financial performance.
Read more →AGIO▲ +14.3%on this newsshared move
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
Agios Pharmaceuticals is advancing its oral pyruvate kinase activator, mitapivat, toward potential accelerated approval from the FDA for treating sickle cell disease. Following a pre-supplemental New Drug Application meeting, the company plans to submit a formal request for approval and is required to conduct a confirmatory clinical trial. The FDA's feedback emphasized the unmet need for treatment options in this condition, and Agios remains committed to expediting the approval process while ensuring rigorous standards are met.
Read more →AGIOAgios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
Agios Pharmaceuticals announced the approval of PYRUKYND (mitapivat) for adults with thalassemia in the UAE, marking it as the only treatment available for this condition in the region. The approval is based on successful Phase 3 trial results, highlighting the drug's potential to significantly improve patient outcomes. Agios, in partnership with NewBridge Pharmaceuticals, aims to enhance treatment access for thalassemia patients across the Gulf region.
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals reported its financial results for Q4 and full year 2025, highlighting the U.S. approval of AQVESME for treating thalassemia. The company aims to drive a successful launch of AQVESME while expanding its pipeline into other rare diseases. Despite a net loss of $108 million in Q4, Agios remains focused on its strategic goals.
Read more →AGIOAgios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
Agios Pharmaceuticals will host a conference call and webcast on February 12, 2026, to discuss its fourth quarter and full year 2025 financial results. The event will be accessible via their website, and a replay will be available shortly after. This initiative reflects Agios's commitment to transparency and communication with stakeholders.
Read more →AGIOAgios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth AQVESME (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA mee
Agios Pharmaceuticals has outlined its strategic priorities for 2026, focusing on the launch of AQVESME (mitapivat) in the U.S. for thalassemia following its FDA approval in December 2025. The company has detailed plans for expanding its rare disease portfolio, including upcoming trials for sickle cell disease and myelodysplastic syndromes. However, AQVESME poses risks of hepatocellular injury that require careful management and monitoring. Agios aims for significant growth, projecting over $1 billion in peak global sales from this launch and expansion of its early-stage pipeline.
Read more →AGIOAgios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Agios Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company's management team is scheduled to speak at 8:15 a.m. PST. A live webcast will be available on their website, with a replay accessible for two weeks post-event.
Read more →AGIO▲ +18.6%on this news
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
Agios Pharmaceuticals has received FDA approval for AQVESME (mitapivat) to treat anemia in adults with alpha- or beta-thalassemia. This marks a significant advancement as AQVESME is the only approved treatment for both transfusion-dependent and non-transfusion-dependent forms of the disease. The approval is based on successful Phase 3 trial results showing improvements in anemia and quality of life, though it comes with a REMS program due to potential liver injury risks.
Read more →AGIOAgios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
Agios Pharmaceuticals has announced that the FDA has yet to make a decision on the supplemental New Drug Application (sNDA) for mitapivat, impacting treatment options for thalassemia patients. The review remains active, but no new data has been submitted or requested by the FDA. Despite ongoing collaboration with the agency, a timeline for the decision has not been provided, posing uncertainty for the company's future actions and potential market introduction of the drug.
Read more →AGIO▼ -50.9%on this news
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
Agios Pharmaceuticals announced positive topline results from the RISE UP Phase 3 trial of mitapivat for sickle cell disease. The trial demonstrated a statistically significant improvement in hemoglobin response compared to placebo, although it did not achieve statistical significance for reducing pain crises. Clinically meaningful benefits in pain and fatigue were observed in patients who achieved hemoglobin response. The company plans to present these results to the FDA for potential regulatory approval.
Read more →AGIO▼ -7.2%on this news
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
Agios Pharmaceuticals announced that new data on mitapivat will be presented at the 67th ASH Annual Meeting. The data emphasizes the drug's potential in treating rare blood disorders such as thalassemia and sickle cell disease. Agios aims to deepen understanding of these conditions through research and community engagement.
Read more →AGIOAgios Reports Third Quarter 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals reported its third quarter 2025 financial results, highlighting a net loss of $103.4 million compared to a net income of $947.9 million in the same quarter of 2024. The company is focusing on key milestones for its drug PYRUKYND in thalassemia and the Phase 3 trial for sickle cell disease. Additionally, enrollment for the Phase 2b trial of tebapivat has been completed, showcasing Agios's ongoing commitment to rare disease treatment.
Read more →AGIOAgios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
Agios Pharmaceuticals announced that the CHMP has issued a positive opinion for PYRUKYND (mitapivat) for treating anemia in adults with thalassemia. This decision is based on results from two Phase 3 trials. The European Commission will review this opinion, with a final decision expected by early 2026. PYRUKYND is already approved in Saudi Arabia for similar indications.
Read more →AGIOAgios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
Agios Pharmaceuticals has announced a conference call and live webcast scheduled for October 30, 2025, at 8:00 a.m. ET to discuss its third quarter financial results and business highlights. The event will be accessible via the company's website, with a replay available shortly after. Agios aims to transform rare disease treatment through innovative medicines.
Read more →AGIO▼ -11%on this news
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
Agios Pharmaceuticals announced that the FDA has extended the PDUFA goal date for the supplemental New Drug Application of PYRUKYND (mitapivat) for thalassemia by three months to December 7, 2025. This extension follows a request from the FDA for a proposed Risk Evaluation and Mitigation Strategy. Agios remains optimistic about the drug's benefit-risk profile, supported by data from Phase 3 trials.
Read more →AGIOAgios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
Agios Pharmaceuticals has received approval from the Saudi Food and Drug Authority for PYRUKYND (mitapivat) to treat adult patients with both non-transfusion-dependent and transfusion-dependent thalassemia. This marks a significant milestone as Saudi Arabia becomes the first country to approve this treatment, providing new hope for patients facing severe symptoms. The approval is based on results from Phase 3 trials and aims to address the unmet medical needs in this patient population.
Read more →AGIOAgios Reports Second Quarter 2025 Financial Results and Provides Business Update $12.5 million in second quarter PYRUKYND (mitapivat) net revenues ended second quarter with $1.3 billion dollars in cash, cash equivalents
Agios Pharmaceuticals announced its financial results for the second quarter of 2025, reporting $12.5 million in net revenues from its product PYRUKYND, an increase from the previous year. The company ended the quarter with $1.3 billion in cash and marketable securities, positioning itself well for future endeavors. They are awaiting FDA approval for PYRUKYND for thalassemia with a decision expected on September 7, 2025. Additionally, Agios is making progress with its clinical trials, including a Phase 3 trial for sickle cell disease, with results due by the end of the year.
Read more →AGIOAgios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
Agios Pharmaceuticals has scheduled a conference call and live webcast for July 31, 2025, at 8:00 a.m. ET to discuss its second quarter financial results and business highlights. The webcast will be accessible through the Investors section of Agios's website, with a replay available shortly after the event. The company is known for its pioneering work in pyruvate kinase activation and has a strong pipeline focusing on therapies for rare diseases.
Read more →AGIOAgios Appoints Dr. Jay Backstrom to Board of Directors
Agios Pharmaceuticals has appointed Dr. Jay Backstrom to its Board of Directors, effective immediately. Dr. Backstrom, a seasoned healthcare executive, will contribute his extensive experience in advancing clinical programs, particularly in rare diseases. His appointment comes at a crucial time as Agios aims to maximize the potential of its PK activator, PYRUKYND, and expand its pipeline of rare disease treatments.
Read more →AGIOAgios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
Agios Pharmaceuticals, Inc. will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025. The presentation will showcase the company's advancements in therapies for rare diseases, including a first-in-class pyruvate kinase activator. A live webcast will be available on their website, with a replay accessible for two weeks post-event.
Read more →AGIOAgios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
Agios Pharmaceuticals announced new data highlighting its pyruvate kinase (PK) activators mitapivat and tebapivat at the upcoming 30th European Hematology Association Congress in Milan. Presentations will include results from pediatric studies showing the benefits of mitapivat in reducing the transfusion burden in PK deficiency patients. Long-term data also point to mitapivat's effectiveness in treating sickle cell disease. However, while findings are promising, there was a caveat in the ACTIVATE-KidsT study where the primary endpoint's statistical criterion was not met.
Read more →AGIOAgios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
Agios Pharmaceuticals is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025. The presentation will be available via a live webcast on the company's website and archived for at least two weeks afterward. Agios is recognized for its pioneering work in PK activation and developing therapies for rare diseases, including a first-in-class treatment for PK deficiency. The company is advancing multiple investigational medicines and continues to build its clinical pipeline in hematologic diseases.
Read more →AGIOAgios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
Agios Pharmaceuticals, Inc. will present at the BofA Securities 2025 Health Care Conference on May 14, 2025. The company's management team will discuss its advancements in cellular metabolism and potential therapies for rare diseases. Agios is recognized for its groundbreaking pyruvate kinase activator and is actively developing medicines for various hematologic conditions. The presentation will be accessible via a live webcast and followed by an archived replay on the company's website.
Read more →AGIOAgios Reports First Quarter 2025 Financial Results and Recent Business Highlights - U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND (mitapivat) in Thalassemia, with PDUFA Goal Date of
Agios Pharmaceuticals reported its first-quarter 2025 financial results, highlighting the acceptance of its supplemental New Drug Application for PYRUKYND in thalassemia, with a goal date of September 7, 2025. The company is also progressing with its Phase 3 RISE UP study for sickle cell disease, targeting topline results by late 2025. Financially, Agios generated $8.7 million in net revenue during the quarter but reported a net loss of $89.3 million. The company maintains a robust cash position of $1.4 billion to support its ongoing development projects.
Read more →AGIOAgios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
Agios Pharmaceuticals, Inc. announced it will host a conference call and live webcast on May 1, 2025, at 8:00 a.m. ET to discuss its first quarter financial results for 2025. The webcast will be available on the company’s website along with a replay shortly after the event. Agios is recognized for its pioneering work in pyruvate kinase activation and is developing therapies for rare diseases, including various hematologic conditions. The company is also advancing a preclinical candidate targeting polycythemia vera.
Read more →AGIOAgios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
Agios Pharmaceuticals announced the grant of inducement equity awards to its newly appointed Chief Corporate Development & Strategy Officer, Krishnan Viswanadhan, effective March 5, 2025. The awards include stock options and restricted stock units as inducements for his employment. This move adheres to Nasdaq Listing Rule 5635(c)(4), underlining the company's commitment to regulatory compliance. Agios continues to develop therapies for rare diseases, particularly through its leadership in pyruvate kinase activation.
Read more →AGIOAgios to Present at Upcoming Investor Conferences
Agios Pharmaceuticals, a leader in cellular metabolism and PK activation, has announced its schedule for upcoming presentations at notable investor conferences. The company will host a fireside chat at the Leerink Global Healthcare Conference on March 11 and at the Barclays Global Healthcare Conference on March 12, 2025. Agios specializes in developing therapies for rare diseases, and their pipeline includes treatments for various conditions such as alpha- and beta-thalassemia and sickle cell disease. These events reflect Agios's ongoing commitment to engaging with investors and communicating developments in its clinical pipeline.
Read more →AGIOAgios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
Agios Pharmaceuticals has announced that its management will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025. The live webcast will be available on the company’s website, and a replay will be archived for two weeks following the event. Agios continues to advance its clinical pipeline, focusing on therapies for rare hematologic diseases, including a first-in-class PK activator for adults with PK deficiency.
Read more →AGIOAgios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
Agios Pharmaceuticals announced that its Phase 3 ACTIVATE-Kids study of mitapivat in children with pyruvate kinase deficiency successfully met its primary endpoint, indicating an increase in hemoglobin levels. This marks a significant advancement as it is the first study to demonstrate the efficacy of an oral treatment for this condition in pediatric patients not receiving regular transfusions. The safety profile observed was consistent with that seen in adult studies. Agios plans to submit a marketing application for mitapivat in this patient demographic following encouraging results from both ACTIVATE-Kids and ACTIVATE-KidsT studies.
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - Filed for Regulatory Approval of Mitapivat (PYRUKYND ) for the Treatment of Adult Patients with Non-Transfusion-Dependent
Agios Pharmaceuticals reported its fourth quarter and full year 2024 financial results, highlighting the filing for regulatory approval of Mitapivat (PYRUKYND) across the U.S., EU, Saudi Arabia, and UAE for thalassemia treatment. The company also completed enrollment in the Phase 3 RISE UP study for sickle cell disease, expecting topline results in late 2025 and potential U.S. launch in 2026. Despite experiencing a net loss in Q4, Agios maintains a strong cash position and outlines key milestones for upcoming regulatory decisions and product launches in the near future.
Read more →AGIOAgios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
Agios Pharmaceuticals, Inc. will host a conference call and live webcast on February 13, 2025, to report its fourth quarter and full year 2024 financial results. The event will begin at 8:00 a.m. ET and will be accessible via the company's website. Agios is recognized for its pioneering role in PK activation, particularly in developing therapies for rare diseases, and it has a strong pipeline that includes treatments for conditions like sickle cell disease and myelodysplastic syndrome. The webcast will also include business highlights, enhancing transparency for investors.
Read more →AGIOAgios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio FDA Accepted Agios Supplemental New Drug Application for PYRUKYND (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dep
Agios Pharmaceuticals announced key milestones for 2025, highlighting the acceptance of its supplemental new drug application for PYRUKYND by the FDA, which targets adult patients with non-transfusion-dependent and transfusion-dependent thalassemia. Additionally, the company plans significant commercial launches and will outline its pipeline expansion during its presentation at the J.P. Morgan Healthcare Conference. Agios emphasized its strong financial position and innovative rare disease pipeline, paving the way for growth in the coming years.
Read more →AGIOAgios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Agios Pharmaceuticals, Inc. announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 15, 2025. The presentation will highlight Agios's leadership in cellular metabolism and its commitment to developing therapies for rare diseases. The company focuses on a clinical pipeline that includes treatments for various hematologic diseases and a potential therapy for polycythemia vera. Investors can access the live webcast on the company's website, with a replay available afterward.
Read more →AGIO▼ -21.1%on this news· ran to -38% by day 3
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
Agios Pharmaceuticals announced positive results from its Phase 3 ENERGIZE-T study of mitapivat, demonstrating significant efficacy in reducing transfusion burdens for patients with transfusion-dependent alpha- or beta-thalassemia. The study met its primary and all key secondary endpoints, leading Agios to file for regulatory approval across the U.S., Europe, Saudi Arabia, and the UAE. Though the treatment shows promise, some patients experienced serious adverse events, including hepatocellular injury, leading to treatment discontinuation. Overall, the findings position mitapivat as a potential new standard of care for thalassemia patients.
Read more →AGIOAgios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
Agios Pharmaceuticals has announced that it will present new data on its PK activators, mitapivat and tebapivat, during the 66th ASH Annual Meeting, which will occur from December 7-10, 2024. The presentations will include results from the Phase 3 ENERGIZE-T study of mitapivat in thalassemia and updates on tebapivat's Phase 1 study in sickle cell disease. These findings are expected to showcase the advancements in Agios' clinical pipeline, targeting various rare blood disorders. An investor event led by the company's leadership will also take place on December 9, 2024, focusing on these developments.
Read more →AGIOAgios Reports Business Highlights and Third Quarter 2024 Financial Results - Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease Topline Data from 52-Week Study Expected in Late 2025 - -
Agios Pharmaceuticals reported significant business advancements and financial results for Q3 2024. The company completed enrollment for the Phase 3 RISE UP study of mitapivat in sickle cell disease and received $1.1 billion in payments following FDA approval. Additionally, Agios commenced the Phase 2b study of tebapivat in lower-risk myelodysplastic syndromes, which has received FDA orphan drug designation. The company's financial position remains robust with considerable revenues and cash reserves, positioning it for future growth and exploration of new therapeutic areas.
Read more →AGIOAgios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
Agios Pharmaceuticals has announced the completion of enrollment in the Phase 3 RISE UP study for mitapivat, a treatment for sickle cell disease. This clinical trial, which involves over 200 patients globally, will assess the efficacy and safety of mitapivat over a 52-week period. Topline results are expected to be available in late 2025, offering insights into the medication's potential impact on the disease. Mitapivat is designed to enhance the glycolytic pathway in red blood cells, addressing a significant medical need in sickle cell disease management.
Read more →AGIOAgios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
Agios Pharmaceuticals, Inc. has announced it will host a conference call and live webcast on October 31, 2024, to report its third quarter 2024 financial results and business highlights. The call will provide insights into the company's financial performance and advancements in its therapeutic pipeline. Agios is notable for its leadership in cellular metabolism and is focused on developing treatments for rare diseases, including a first-in-class therapy for PK deficiency. Details on the call will be accessible through the company's website.
Read more →AGIOAgios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
Agios Pharmaceuticals announced that the FDA has granted orphan drug designation to its drug tebapivat (AG-946) for the treatment of myelodysplastic syndromes (MDS). This designation helps facilitate the development of therapies for rare diseases and qualifies Agios for various regulatory incentives. Tebapivat aims to be the first oral treatment for anemia in lower-risk MDS, a condition affecting around 75,000-80,000 patients in the U.S. and EU. The company is currently transitioning from a Phase 2a to a Phase 2b study of tebapivat in this indication.
Read more →AGIOAgios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
Agios Pharmaceuticals announced its scheduled presentation at the 2024 Cantor Global Healthcare Conference on September 18, 2024, at 10:20 a.m. ET. The company is known for pioneering therapies based on cellular metabolism and has a significant focus on treatments for rare diseases. Agios markets a disease-modifying therapy for PK deficiency and is advancing a range of investigational medicines for various hematologic conditions, including thalassemia and sickle cell disease.
Read more →AGIOAgios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
Agios Pharmaceuticals has announced it will receive $1.1 billion in milestone payments following FDA approval of vorasidenib for Grade 2 astrocytoma and oligodendroglioma. The payments, including $905 million from Royalty Pharma and $200 million from Servier, will significantly bolster Agios's cash position to $1.7 billion by mid-2024. The approval of vorasidenib is a noteworthy achievement, being the first in over two decades for this specific glioma grade. This financial boost supports Agios's planned launches of PYRUKYND for thalassemia and sickle cell disease in the coming years.
Read more →AGIOAgios Reports Business Highlights and Second Quarter 2024 Financial Results - Reported Positive Topline Data from Phase 3 ENERGIZE-T Study Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Tha
Agios Pharmaceuticals reported strong business highlights and financial results for Q2 2024, featuring positive topline data from the Phase 3 ENERGIZE-T study of mitapivat. The company plans to file a supplemental New Drug Application by the end of the year, aiming to leverage positive outcomes from both ENERGIZE and ENERGIZE-T studies. Additionally, Agios secured a major agreement with Royalty Pharma, positioning itself for substantial financial gains upon FDA approval of vorasidenib. However, the company also reported an increased net loss and rising research expenses during this period.
Read more →AGIOAgios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
Agios Pharmaceuticals announced topline results from its Phase 3 ACTIVATE-KidsT study of mitapivat in children with PK deficiency who are regularly transfused. While the primary endpoint for transfusion reduction was not met, the study revealed that 28.1% of participants in the mitapivat arm achieved a meaningful reduction compared to 11.8% in the placebo group. The safety profile aligned with prior adult studies, indicating that mitapivat is generally safe and well-tolerated. This study represents Agios' first pediatric data readout, furthering its mission to address rare diseases.
Read more →AGIOAgios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
Agios Pharmaceuticals will hold a conference call on August 1, 2024, to report their financial results for the second quarter of 2024. The conference will include business highlights and is accessible via a live webcast. Agios is known for its pioneering PK activator therapy for PK deficiency and is actively developing treatments for a range of rare diseases. The company has a promising clinical pipeline advancing multiple investigational medicines.
Read more →AGIOAgios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
Agios Pharmaceuticals presented promising results from its Phase 3 ENERGIZE study of mitapivat for adults with non-transfusion-dependent thalassemia at the European Hematology Association 2024 Hybrid Congress. The study met its primary endpoint, demonstrating a statistically significant increase in hemoglobin response and improvements in fatigue and exercise capacity among treated patients. Results support the potential of mitapivat as a foundational oral treatment option for various thalassemia subtypes. Agios plans to seek regulatory approval for mitapivat in the U.S. by the end of the year.
Read more →AGIO▲ +20.6%on this news· ran to +32% by day 3
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
Agios Pharmaceuticals announced today that its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent thalassemia achieved its primary endpoint by demonstrating a statistically significant reduction in transfusion burdens compared to a placebo. All key secondary endpoints also met statistical significance, suggesting the potential of mitapivat as an oral disease-modifying treatment for thalassemia. Agios plans to submit a U.S. marketing application for mitapivat by the end of 2024, based on the promising results from both the ENERGIZE and ENERGIZE-T studies. The company also aims to present further analysis at upcoming medical meetings.
Read more →AGIOAgios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
Agios Pharmaceuticals, Inc. announced its upcoming presentation at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. The announcement highlights Agios' role as a leader in cellular metabolism and its dedication to providing innovative therapies for rare diseases. The company currently markets a first-in-class PK activator for PK deficiency and is advancing several programs in hematologic conditions. A live webcast of the event will be available on Agios' website, ensuring accessibility for interested stakeholders.
Read more →AGIO▲ +23.2%on this newsshared move
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty Royalty Pharma to Acquire Rights to Agios 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of Voraside
Agios Pharmaceuticals has entered into a $905 million purchase agreement with Royalty Pharma for a 15% royalty on potential U.S. net sales of vorasidenib. The agreement stipulates that Agios will receive this payment upon FDA approval, scheduled for August 20, 2024. Additionally, Agios retains rights to a $200 million milestone payment from Servier and continues to maintain a 3% royalty on sales exceeding $1 billion. This transaction is expected to provide Agios with significant financial flexibility for future developments and expansions in its pipeline.
Read more →AGIOAgios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
Agios Pharmaceuticals announced that it will present clinical data at the European Hematology Association Congress 2024 in Madrid. Key highlights include findings from the Phase 3 ENERGIZE study of mitapivat, which will be showcased in both a plenary and poster session. In addition, Agios will examine the design of the Phase 3 RISE UP study focused on sickle cell disease, indicating the company's continued commitment to advancing treatments for rare blood disorders.
Read more →AGIOAgios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024
Agios Pharmaceuticals, Inc. is set to present at the BofA Securities 2024 Health Care Conference on May 16, 2024. The presentation will highlight the company's leadership in cellular metabolism and PK activation, as well as their innovative therapies for rare diseases. Agios continues to advance a clinical pipeline, including treatments for conditions such as sickle cell disease and phenylketonuria (PKU). Investors can access the live webcast on the company's website.
Read more →AGIOAgios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
Agios Pharmaceuticals, a leader in cellular metabolism, has announced its participation in the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024. During this event, the company will present its advancements in PK activation and its ongoing commitment to developing therapies for rare diseases. Agios markets a first-in-class PK activator for adult patients with PK deficiency, reflecting its pioneering role in addressing rare, debilitating conditions. The company is also advancing several investigational medications for various hematologic diseases.
Read more →AGIOAgios Reports Business Highlights and First Quarter 2024 Financial Results - Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expecte
Agios Pharmaceuticals reported highlights and financial results for the first quarter of 2024, including positive outcomes from the Phase 3 ENERGIZE study of mitapivat for non-transfusion-dependent thalassemia. The company anticipates topline data from the ENERGIZE-T study for transfusion-dependent thalassemia in Q2 2024. Despite experiencing a net loss of $81.5 million for the quarter, Agios maintains a strong cash position with $714.3 million available. The firm is also focusing on launching mitapivat in the near future and expanding its research pipeline in various rare diseases.
Read more →AGIOAgios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
Agios Pharmaceuticals, Inc. will host a conference call and live webcast on May 2, 2024, to discuss its first quarter 2024 financial results and key business updates. The event highlights Agios's role in pioneering therapies for rare diseases and demonstrates its commitment to pioneering PK activation treatments. The presentation will be available on the company's website, providing insights into its financial performance and ongoing initiatives in rare hematologic diseases. An archived version of the webcast will also be accessible for at least two weeks after the event.
Read more →AGIO▲ +7.3%on this news
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
Agios Pharmaceuticals has published its 2024 Environmental, Social and Governance (ESG) Report, detailing its sustainability efforts from January 1 to December 31, 2023. The report highlights the company's initiatives in promoting diversity, equity, and inclusion within clinical trials, as well as within the organization and the life sciences industry. CEO Brian Goff emphasizes Agios' commitment to not just financial performance, but also doing what is right for patients and the community. The ESG program is overseen by the board of directors and represents a coordinated effort across various corporate functions.
Read more →AGIOAgios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) will present at the Leerink Partners Global Biopharma Conference on March 12, 2024. The presentation time is set for 10:00 a.m. ET, and it will also be accessible via a live webcast on their website. Agios is recognized for its pioneering work in cellular metabolism and therapies for rare diseases, including a first-in-class treatment for PK deficiency. The company continues to develop a strong pipeline of investigational medicines targeting various hematologic diseases.
Read more →AGIO▲ +11.1%on this news· ran to +30% by day 3
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
Agios Pharmaceuticals, Inc. will present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. The company is known for its pioneering work in cellular metabolism therapies aimed at rare diseases. Agios provides innovative therapies, including a first-in-class treatment for PK deficiency, and is advancing multiple investigational medicines for various conditions. The live presentation will be accessible via webcast, with an archived replay available afterward.
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- o
Agios Pharmaceuticals released its fourth quarter and full year 2023 financial results, highlighting positive developments in its clinical trials for mitapivat. The company reported promising data from the Phase 3 ENERGIZE study for non-transfusion-dependent thalassemia and the Phase 2 RISE UP study in sickle cell disease. Despite a decrease in net revenue for PYRUKYND and an increase in net loss year-over-year, Agios maintains a strong cash position and anticipates multiple upcoming catalysts, including additional Phase 3 readouts in 2024. The firm aims to position itself as a leader in rare diseases with its innovative therapeutic pipeline.
Read more →AGIOAgios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
Agios Pharmaceuticals, a leader in cellular metabolism therapies, has announced a conference call scheduled for February 15, 2024, to discuss its fourth quarter and year end 2023 financial results. The event demonstrates the company's commitment to investor transparency and engagement. Agios continues to advance its clinical pipeline in rare diseases, including treatments for PK deficiency and other hematologic conditions.
Read more →AGIO▲ +5.7%on this news
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data
Agios Pharmaceuticals has announced key milestones for its rare disease portfolio, highlighting recent positive Phase 3 data for mitapivat in non-transfusion-dependent thalassemia. The company expects to achieve four additional Phase 3 readouts by the end of 2025, aiming for FDA approvals in thalassemia by 2025 and in sickle cell disease by 2026. Agios's robust cash position is anticipated to support the advancement of ongoing programs and disciplined pipeline expansion until at least 2026. The announcement will be presented at the 42nd Annual J.P. Morgan Healthcare Conference.
Read more →AGIO▲ +5.2%on this newsshared move
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
Agios Pharmaceuticals announced that its Phase 3 ENERGIZE study of mitapivat achieved its primary endpoint of hemoglobin response in adults with non-transfusion-dependent alpha- or beta-thalassemia. The study demonstrated statistically significant results for both key secondary endpoints, including changes in FACIT-Fatigue Score and hemoglobin concentration. The data from this study could position mitapivat as the first oral treatment for this patient population, addressing a significant unmet medical need. Agios plans to file for regulatory approval by the end of 2024 following further analysis and results from an ongoing study.
Read more →AGIOAgios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Agios Pharmaceuticals, Inc. has announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2024. The presentation will highlight the company’s advancements in therapies aimed at rare diseases, including a first-in-class treatment for pyruvate kinase deficiency. Agios continues to focus on developing a robust clinical pipeline with investigational medicines for various blood disorders. The event is expected to showcase Agios' leadership and innovative approaches in the realm of cellular metabolism.
Read more →AGIOAgios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
Agios Pharmaceuticals has announced positive results from the Phase 2 portion of the RISE UP study regarding mitapivat for sickle cell disease. The results demonstrated a significant improvement in hemoglobin levels and a reduction in pain crises compared to placebo. The company plans to proceed with the Phase 3 study and aims for potential U.S. approval as early as 2026. Overall, the data support mitapivat's therapeutic potential for patients suffering from this challenging condition.
Read more →AGIOAgios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
Agios Pharmaceuticals has announced successful clinical proof-of-concept results for AG-946 in a Phase 2a trial targeting anemia in lower-risk myelodysplastic syndromes. Four out of 10 patients in the low transfusion burden cohort achieved transfusion independence, and the safety profile aligned with previous studies. With encouraging results, Agios plans to initiate a Phase 2b study in mid-2024. The company aims to further evaluate AG-946's efficacy in treating anemia and present comprehensive data at an upcoming medical meeting.
Read more →AGIOAgios Reports Business Highlights and Third Quarter 2023 Financial Results - First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease - - Completed Enrollment in Phase 3 ACT
Agios Pharmaceuticals reported its business highlights and financial results for the third quarter of 2023. The company celebrated the dosing of the first patient in the Phase 3 RISE UP study for mitapivat in sickle cell disease and completed enrollment for the pediatric PK deficiency study. Other upcoming milestones include topline data from multiple trials expected within the next year. Despite these advancements, Agios reported a net loss of $91.3 million, reflecting increased R&D expenses driven by a significant partnership payment.
Read more →AGIOAgios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
Agios Pharmaceuticals announced that it will present clinical and translational data at the upcoming 65th ASH Annual Meeting in San Diego, focusing on rare blood disorders. The highlights include statistically significant hemoglobin responses from the RISE UP study's Phase 2 portion, which support advancing to Phase 3. Agios will showcase various abstracts relating to pyruvate kinase deficiency, thalassemia, and sickle cell disease, as well as new data on the investigational drug AG-946. Additionally, the company will host a live investor event prior to the meeting.
Read more →AGIOAgios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
Agios Pharmaceuticals, Inc. will host a conference call and live webcast on November 2, 2023, to present its third quarter financial results and other business updates. The webcast will be accessible on Agios' website, where a replay will be available for at least two weeks. The company is recognized for its pioneering therapies for rare diseases and has an extensive clinical pipeline focused on hematologic disorders.
Read more →AGIOAgios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
Agios Pharmaceuticals announced that it will present at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023. The company's presentation will focus on its leadership in cellular metabolism and therapies for rare diseases. Agios markets a first-in-class pyruvate kinase activator and is advancing various investigational medicines targeting conditions like thalassemia and sickle cell disease. A live webcast and subsequent replay of the presentation will be available on their website.
Read more →AGIOAgios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
Agios Pharmaceuticals has secured an exclusive worldwide license from Alnylam Pharmaceuticals for a novel siRNA targeting TMPRSS6, aimed at treating Polycythemia Vera (PV). This collaboration leverages Agios' expertise in hematologic diseases alongside Alnylam's advanced siRNA platform. The agreement includes an upfront payment of $17.5 million and potential milestone payments totaling up to $130 million. Clinical studies are set to begin this year, with hopes for a transformative treatment for the approximately 100,000 patients affected by PV in the U.S.
Read more →AGIOAgios Reports Business Highlights and Second Quarter 2023 Financial Results - Announced Positive Results from Phase 2 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease On Track to Enroll First Pati
Agios Pharmaceuticals reported significant business developments and Q2 financial results, highlighting positive results from the Phase 2 RISE UP trial of mitapivat for sickle cell disease. They completed enrollment in critical Phase 3 studies of mitapivat for thalassemia. Additionally, Agios announced an exclusive license agreement with Alnylam for potential treatments and reported a cash position of $946 million. There were also increases in PYRUKYND revenues, signaling growth in their product offerings.
Read more →AGIOAgios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
Agios Pharmaceuticals, Inc. will host a conference call and webcast on August 3, 2023, to discuss its second quarter financial results and other business developments. The company has established itself as a leader in cellular metabolism, particularly in therapies for rare diseases. Agios markets a first-in-class PK activator for adults with PK deficiency and is advancing a clinical pipeline that includes treatments for various hematological conditions. The webcast will also be archived on their website for future access.
Read more →AGIOAgios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
Agios Pharmaceuticals disclosed positive findings from the Phase 2 portion of its RISE UP study of mitapivat in sickle cell disease. The study achieved its primary efficacy endpoint, with approximately half of patients in both active treatment arms showing significant hemoglobin response compared to placebo. Additionally, there was a noted trend in reduced pain crises. Agios plans to advance into the Phase 3 portion of the study, expecting to enroll the first patient in Q4 2023 and aiming for U.S. approval by 2026.
Read more →AGIOAgios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023
Agios Pharmaceuticals, Inc. announced its participation in the Goldman Sachs 44th Annual Global Healthcare Conference scheduled for June 15, 2023. The presentation will be accessible via a live webcast on the company's website, with a replay available for two weeks afterward. Agios continues to advance its pipeline of therapies focusing on rare diseases, contributing to its reputation as a leader in cellular metabolism.
Read more →AGIOAgios Appoints Catherine Owen to Board of Directors
Agios Pharmaceuticals has appointed Catherine Owen to its board of directors, effective June 13, 2023, following the departure of John Maraganore after nearly 12 years. Kaye Foster will assume the role of lead independent director. With almost 30 years in the pharmaceutical industry, Owen's expertise in market commercialization is expected to significantly benefit Agios, especially as the company approaches key product launches for thalassemia and sickle cell disease. Agios has a robust pipeline targeting rare diseases.
Read more →AGIOAgios to Present Clinical and Translational Data at European Hematology Association Annual Congress
Agios Pharmaceuticals announced plans to present a range of clinical and translational data at the European Hematology Association Annual Congress. The presentations will cover new analyses from studies on PYRUKYND® (mitapivat), focusing on its benefits for patients with PK deficiency. Additionally, updated real-world data regarding the burden of PK deficiency and thalassemia will also be shared. These insights contribute to Agios' commitment to developing therapies for rare diseases.
Read more →AGIO▲ +7.7%on this news
Agios Reports Business Highlights and First Quarter 2023 Financial Results On Track for PYRUKYND (mitapivat) Data Readouts of the Phase 2 Portion of the RISE UP Study in Sickle Cell Disease in Mid-2023 and the Phase 3 EN
Agios Pharmaceuticals reported its first quarter 2023 financial results, highlighting a net revenue of $5.6 million from PYRUKYND and significant progress in its clinical studies across various rare diseases. The company anticipates data readouts from the Phase 2 RISE UP study in sickle cell disease and the completion of enrollment in Phase 3 ENERGIZE and ENERGIZE-T studies for thalassemia by mid-year. Despite a net loss of $81.0 million during the quarter, Agios maintains a strong cash position to support its development plans.
Read more →AGIOAgios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
Agios Pharmaceuticals is scheduled to present at the RBC Capital Markets Global Healthcare Conference on May 16, 2024. The presentation will showcase the company's advancements in therapies for rare diseases, including their first-in-class pyruvate kinase activator. Agios emphasizes its commitment to developing a clinical pipeline that targets conditions such as alpha- and beta-thalassemia and sickle cell disease. Live webcasts of the presentation will be available on their website.
Read more →AGIOAgios Appoints Jeffrey Capello to Board of Directors
Agios Pharmaceuticals announced the appointment of Jeffrey Capello to its board of directors, following Paul Clancy's decision to step down at the end of his term. Capello brings nearly 30 years of experience in driving growth for life sciences companies, enhancing the company's leadership. The CEO of Agios expressed enthusiasm for Capello's international perspective and expertise, which are expected to contribute significantly to the company's mission in rare disease therapies. Agios continues to prioritize diverse leadership to bolster value for patients and shareholders.
Read more →AGIO▲ +5.3%on this news
Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023
Agios Pharmaceuticals, Inc. will host a conference call on May 4, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results and other business highlights. The event will be available via live webcast, which can be accessed through Agios's website. The company is known for its commitment to developing therapies for rare diseases, including a first-in-class therapy for pyruvate kinase deficiency and a diverse clinical pipeline across various conditions.
Read more →AGIOAgios Publishes 2023 Environmental, Social and Governance (ESG) Report
Agios Pharmaceuticals has published its 2023 Environmental, Social and Governance (ESG) Report, highlighting efforts in patient access, health equity, and workplace diversity. Key initiatives include support for patients eligible for the company's PYRUKYND® treatment and ongoing commitment to creating a diverse and inclusive workplace. The report aligns with SASB standards and UN Sustainable Development Goals, showcasing Agios' dedication to sustainability and ethical business practices. The board oversees ESG strategies to enhance long-term value for stakeholders.
Read more →AGIOAgios to Participate in March Investor Conferences
Agios Pharmaceuticals is set to participate in two key investor conferences in March 2023. The Cowen 43rd Annual Health Care Conference is scheduled for March 6, and the Oppenheimer 33rd Annual Healthcare Conference will take place on March 13. These presentations will highlight Agios's advancements in therapies for rare diseases, including their leadership in cellular metabolism and a robust clinical pipeline.
Read more →AGIOAgios Launches “Red Cell Revolution” in Recognition of Rare Disease Day
Agios Pharmaceuticals has launched the 'Red Cell Revolution' advocacy council on Rare Disease Day to support individuals affected by hemolytic anemias such as PK deficiency, thalassemia, and sickle cell disease. This initiative aims to unite patients, caregivers, and physicians to share insights and raise awareness about these rare conditions. The council seeks to address the unique challenges faced by these communities and inform Agios's mission to improve care and outcomes. Agios also participates in various initiatives throughout February to further support rare disease communities.
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2022 Financial Results - Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND (mitapivat)in Sickle Cell Disease - - On Track to Complete Enrollment in Phase 3 ENERGIZE and
Agios Pharmaceuticals has reported its financial results for the fourth quarter and full year 2022, highlighting significant advancements in their clinical pipeline and financial standing. The company completed enrollment in the Phase 2 RISE UP study of PYRUKYND for sickle cell disease and is on track with Phase 3 studies for thalassemia. Agios also gained approval for PYRUKYND in the U.S., EU, and Great Britain, supporting the launch and growth of this product. Despite a net loss for 2022, the company holds a strong cash position, anticipating further developments and additional indications by 2026.
Read more →AGIOAgios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
Agios Pharmaceuticals announced it will hold a conference call and live webcast on February 23, 2023, to report its fourth-quarter and year-end 2022 financial results. The event will provide an overview of the company's business highlights and financial performance. Agios, known for its work in cellular metabolism, also markets innovative therapies for rare diseases and maintains a strong clinical pipeline across various conditions.
Read more →AGIOAgios Unveils 2023-2026 Value-driving Catalysts Enabling Company s Vision to Transform Patient Outcomes in Rare Diseases Consistent and compelling clinical data across rare hematological diseases support five ongoing piv
Agios Pharmaceuticals has outlined its strategic milestones and catalysts through 2026 aimed at transforming patient outcomes in rare diseases. The company supports five pivotal clinical trials and anticipates FDA approvals for PYRUKYND in thalassemia and sickle cell disease by 2025 and 2026, respectively. With a robust cash position, Agios plans to expand its portfolio while establishing a classical hematology franchise. The company is also set to launch its first disease-modifying therapy for adult PK deficiency, marking a significant advancement in patient care.
Read more →AGIOAgios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
Agios Pharmaceuticals announced the grant of inducement equity awards to Tsveta Milanova, its newly appointed Chief Commercial Officer, under Nasdaq Listing Rule 5635(c)(4). The grants include stock options, restricted stock units, and performance stock units, all aimed at incentivizing her employment with the company. The moves are part of Agios's ongoing strategy to strengthen its leadership team and enhance its focus on rare disease therapies, including advancements in its clinical pipeline.
Read more →AGIOAgios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 41st Annual J.P. Morgan Healthcare
Read more →AGIOAgios Presents Updated PYRUKYND (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
– Data Suggest Long-term Treatment with PYRUKYND® in Adults with PK Deficiency is Associated with Improvements in Hemoglobin, Iron Overload, Transfusion Burden and Patient-reported Outcomes, Regardless of Transfusion Status – – Additional Data Presented at ASH Characterize Disea
Read more →AGIOAgios Presents Updated PYRUKYND (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α- or β-Thalassemia, Respectively – – Agios to Host Live and Webcast Investor Event on Dec. 12, 2022, at 7 a.m. CT – CAMBRIDGE, M
Read more →AGIOAgios Appoints Tsveta Milanova as Chief Commercial Officer
Agios Appoints Tsveta Milanova as Chief Commercial Officer CAMBRIDGE, Mass., December 6, 2022 Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the appointment of Tsveta Milanova to t
Read more →AGIOAgios to Participate in December Investor Conference
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Bank of America 2022 Virtual Biotec
Read more →AGIO▼ -5.2%on this news
Agios Reports Business Highlights and Third Quarter 2022 Financial Results - U.S. PYRUKYND (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion Net Revenue of $
Agios Reports Business Highlights and Third Quarter 2022 Financial Results - U.S. PYRUKYND (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion Net Revenue of $3.5 Million in Q3 - - Received Positive CHMP Opinion for P
Read more →AGIO▼ -5.2%on this news
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition
– Long-term Data for PYRUKYND® (mitapivat) in Adults with Pyruvate Kinase (PK) Deficiency and Adults with Thalassemia Demonstrate Sustained Improvement in Hemoglobin, Markers of Hemolysis and Other Disease Impacts – – New Data from Single Ascending Dose (SAD) and Multiple Ascend
Read more →AGIOAgios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO Royalty Sagard Healthcare Partners Acquires Rights to Agios 5% Royalty on TIBSOVO U.S. Net Sales CAMBRIDGE, Mass. and TORONTO
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO Royalty Sagard Healthcare Partners Acquires Rights to Agios 5% Royalty on TIBSOVO U.S. Net Sales CAMBRIDGE, Mass. and TORONTO, October 27, 2022 Agios Pharmaceuticals, Inc. (NASDAQ: AGI
Read more →AGIOAgios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the company will host a conference call and live webcast on
Read more →AGIOAgios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the grant of inducement equity awards outside of the Compa
Read more →AGIO▲ +5.2%on this news
Agios Appoints Cecilia Jones as Chief Financial Officer
Agios Appoints Cecilia Jones as Chief Financial Officer CAMBRIDGE, Mass., September 19, 2022 Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the appointment
Read more →AGIO▼ -9.5%on this newsshared move
Agios Receives Positive CHMP Opinion for PYRUKYND (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
CAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced that the Committee for Medicinal Products for Human Use (C
Read more →AGIO▲ +6.4%on this news
Agios to Participate in September Investor Conferences
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced that the company is scheduled to present at the following S
Read more →AGIOAgios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND (mitapivat) for Adults with Pyruvate Kinase Deficiency
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Regularly Transfused, PYRUKYND® Demonstrated a Statistically Significant and Clinically Meaningful Reduction in Transfusion Burden – – Following FDA Approval in February, PYRUKYND® Is the First and Only Disease-Modifying T
Read more →AGIOAgios Appoints Rahul Ballal and Cynthia Smith to Board of Directors
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the appointments of Rahul Ballal, Ph.D., chief executive officer of
Read more →AGIOAgios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer
CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the grant of inducement equity awards outside of the company’s 2013
Read more →AGIO▲ +14.7%on this newsshared move
Agios Reports Business Highlights and Second Quarter 2022 Financial Results Generated $3.1 Million in Net U.S. Revenue for First Full Quarter of PYRUKYND (mitapivat) Sales Brian Goff to Become Chief Executive Officer at
Agios Reports Business Highlights and Second Quarter 2022 Financial Results Generated $3.1 Million in Net U.S. Revenue for First Full Quarter of PYRUKYND (mitapivat) Sales Brian Goff to Become Chief Executive Officer at Agios on August 8, 2022, Leveraging 30+ Years of Biophar
Read more →AGIOAgios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday
Read more →AGIOAgios Appoints Brian Goff as Chief Executive Officer Current CEO, Jackie Fouse, Ph.D., to Transition to Chair of Board of Directors Effective
Agios Appoints Brian Goff as Chief Executive Officer Current CEO, Jackie Fouse, Ph.D., to Transition to Chair of Board of Directors Effective August 8, 2022 Agios to Host Investor Webcast Today at 4:30pm ET CAMBRIDGE, Mass., July 12, 2022 Agios Pharmaceuticals, Inc. (NASDAQ: A
Read more →AGIO▼ -5.6%on this news
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
– Treatment with PYRUKYND® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at Least Once – – PYRUKYND®-Treated Patients Reported Significant Improvements in PK
Read more →AGIOAgios Announces Evolution of Research Organization
– Sarah Gheuens, M.D., Ph.D., to be Named Head of R&D, Chief Medical Officer; Chief Scientific Officer Bruce Car to Step Down at the End of July – – Company to Focus Internal Research Efforts on Late Lead-Optimization Programs, Including PAH Stabilizers and BCAT2 Inhibitors, and
Read more →AGIOAgios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of PYRUKYND® (mitapivat) in Adults with PK Deficiency Who Do Not Receive Regular Transfusions – – Agios to Present New Clinical Data Demonstrating the Normalization of Hemoglobin Levels with
Read more →AGIO▲ +6.7%on this newsshared move
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that the company is scheduled to present at the RBC Capital Markets G
Read more →AGIOAgios Reports Business Highlights and First Quarter 2022 Financial Results Received U.S. FDA Approval for PYRUKYND , the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency
Agios Reports Business Highlights and First Quarter 2022 Financial Results Received U.S. FDA Approval for PYRUKYND , the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency and Agios First Genetically Defined Disease Medicine, U.S.
Read more →AGIO▼ -5.4%on this news
Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company will host a conference call and live webcast on Thursda
Read more →AGIO▼ -5.4%on this news
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND (mitapivat) for Adults with Pyruvate Kinase Deficiency
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly Increased Hemoglobin Level, Decreased Hemolysis and Improved Patient-Reported Outcomes – – Following FDA Approval in February, PYRUKYND® Is the First and Only Disease-Modif
Read more →AGIO▲ +5.7%on this news· ran to +17% by day 3shared move
Agios Reports Fourth Quarter and Full Year 2021 Financial Results Received FDA Approval of PYRUKYND (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy
Agios Reports Fourth Quarter and Full Year 2021 Financial Results Received FDA Approval of PYRUKYND (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder First Patients Dosed in All
Read more →AGIO▼ -5.2%on this news
Agios Announces FDA Approval of PYRUKYND (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
– Approval Based on Results from ACTIVATE and ACTIVATE-T Phase 3 Studies, Supports Treatment of Adults with PK Deficiency Regardless of Transfusion Status – – Company to Provide Robust Patient Access Programs, Including $0 Copays and Free Medication for Eligible Patients – – Ag
Read more →AGIOAgios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday
Read more →AGIOAgios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases
– Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February – – Five Pivotal Clinical Trials are Planned and Ongoing in Thalassemia, Sickle Cell Disease and Pediatric PK Deficiency – – Agios is Expanding
Read more →AGIOAgios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Heal
Read more →AGIO▲ +7.1%on this news
Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
– Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize Bone Mineral Density in PK Deficiency Patients – – Mitapivat Is Under Regulatory Review in the U.S. and EU as a Potential Treatment for Adu
Read more →AGIO▲ +7.1%on this news
Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition
– Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients – – Safety Profile Consistent with Previously Reported Clinical Data – – Agios Announces Initiation of Phase 2/3 RISE UP Study of Mitapivat in Adults with Sickle Cell Disease – – Ag
Read more →AGIOAgios Appoints Richa Poddar as Chief Commercial Officer
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the appointment of Richa Poddar to the role of chief commercial officer, effective D
Read more →AGIO▼ -7%on this news
Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition
– Extension Data for Mitapivat in PK Deficiency and Thalassemia Demonstrate Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis – – New Data from Two Investigator Sponsored Studies of Mitapivat in Sickle Cell Disease Continue to Support Advanc
Read more →AGIOAgios Reports Business Highlights and Third Quarter 2021 Financial Results Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for
Agios Reports Business Highlights and Third Quarter 2021 Financial Results Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for Feb. Initiated ENERGIZE and ENERGIZE-T Phase 3 Studies in Thalassemia Agio
Read more →AGIOAgios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the company will host a conference call and live webcast on Wednesday, Nov. 3, 2021,
Read more →AGIOAgios To Present at September Investor Conferences
CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that the company is scheduled to present
Read more →AGIOAgios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that the U.S. Food and Drug Administratio
Read more →AGIOAgios Reports Business Highlights and Second Quarter 2021 Financial Results Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU Presented Dat
Agios Reports Business Highlights and Second Quarter 2021 Financial Results Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU Presented Data from ACTIVATE and ACTIVATE-T Phase 3 Studies and Thalass
Read more →AGIOAgios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021
CAMBRIDGE, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, July 29,
Read more →AGIOAgios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that it has submitted a Marketing Authori
Read more →AGIOAgios Launches myAgios Patient Support Services for Pyruvate Kinase Deficiency
CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced the launch of myAgios® patient support se
Read more →AGIOAgios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that it has submitted a New Drug Applicat
Read more →AGIOAgios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 – – Agios to Host Investor Webcast Today at 7:30 a.m. ET – CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Agios
Read more →AGIOAgios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent - and -Thalassemia at the European Hematology Association Virtual Congress Study Met Primary Endpoint; Treatment with Mitapivat
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent - and -Thalassemia at the European Hematology Association Virtual Congress Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of 1.0 g/dL in 16 of 20 (80%
Read more →AGIOAgios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress
– Agios to Host Investor Webcast on June 11 at 7:30 a.m. ET – CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that mitapivat clinical
Read more →AGIOAgios Reports Business Highlights and First Quarter 2021 Financial Results Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia A
Agios Reports Business Highlights and First Quarter 2021 Financial Results Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress Com
Read more →AGIOAgios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, April 29
Read more →AGIOAgios Announces Closing of Oncology Business Sale to Servier Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio Agios Enters Into Agreement to Rep
Agios Announces Closing of Oncology Business Sale to Servier Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from
Read more →AGIOAgios Shareholders Approve Sale of Oncology Business to Servier
Agios Shareholders Approve Sale of Oncology Business to Servier CAMBRIDGE, Mass., March 25, 2021 Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that its shareholders voted to approv
Read more →AGIOAgios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell
Read more →AGIOAgios Submits Supplemental New Drug Application to FDA for TIBSOVO (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the
Read more →AGIOAgios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias
– In Partnership with the Sickle Cell Community Consortium, Agios Works to Address Educational Resource Gaps Caused by COVID-19 for Students with Sickle Cell Disease – – Company to Host Facebook Live Discussion with Pyruvate Kinase (PK) Deficiency Patient, Caregiver and Key Opin
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2020 Financial Results Strong Commercial Execution for Second Full Year of TIBSOVO with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 Sale of Oncology Port
Agios Reports Fourth Quarter and Full Year 2020 Financial Results Strong Commercial Execution for Second Full Year of TIBSOVO with Fourth Revenue of $39.1M and $121.1M for Full Year 2020 Sale of Oncology Portfolio Expected to Close Around March 31 Subject to March 25 Sharehol
Read more →AGIOAgios to Present at March Investor Conferences
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the following March investor c
Read more →AGIOAgios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday
Read more →AGIOAgios Pharmaceuticals, Inc. Index to Consolidated Financial Statements Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets F-4 Consolidated Statements of Operations F-5 Consolidated St
Agios Pharmaceuticals, Inc. to Consolidated Financial Statements Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets F-4 Consolidated Statements of Operations F-5 Consolidated Statements of Comprehensive Loss F-6 Consolidated Stat
Read more →AGIOAgios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused 37 Percent of Patients Treated with Mitapivat Achieved 33% Reduction
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused 37 Percent of Patients Treated with Mitapivat Achieved 33% Reduction in Transfusion Burden Compared to Individual Historical T
Read more →AGIOAgios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) r
Read more →AGIOAgios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation Company Expects to File for Regulatory Approval for Mitapivat for the Treat
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in th
Read more →AGIOAgios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the virtual 39th Annual J.P. M
Read more →AGIOAgios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties Agios to Dedicate All Resources to Adv
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initi
Read more →AGIOAgios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease Treatment with Mitapivat Induced Hemoglobin Increase of 1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Pati
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease Treatment with Mitapivat Induced Hemoglobin Increase of 1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients, Decreased Markers of Hemolysis, Reduced 2,3-DPG and
Read more →AGIOAgios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused 40 Percent of Patients Treated with Mitapivat Achieved a Su
Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused 40 Percent of Patients Treated with Mitapivat Achieved a Sustained Hemoglobin Increase of 1.5 g/dL Compared to 0 Pla
Read more →AGIOAgios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the launch of Anemia ID, a program providing no-cost genetic testing for patients
Read more →AGIOAgios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Piper Sandler 32nd Annual Virtual
Read more →AGIOAgios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designa
Read more →AGIOAgios Reports Business Highlights and Third Quarter 2020 Financial Results Third Quarter TIBSOVO Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO Net U.S. Revenue Guidance to $113 115 Million Topline Data from
Agios Reports Business Highlights and Third Quarter 2020 Financial Results Third Quarter TIBSOVO Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO Net U.S. Revenue Guidance to $113 115 Million Topline Data from the Mitapivat Phase 3 ACTIVATE Trial in Non-Transfusion D
Read more →AGIOAgios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that a broad set of clinical and translational data from its oncology and rare ge
Read more →AGIOAgios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a webinar focused on its pyruvate kinase-R (PKR) activ
Read more →AGIOAgios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, Novem
Read more →AGIOAgios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia
– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO® in Newly Diagnosed AML Patients – CAMBRIDGE, Mass., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic
Read more →AGIOAgios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients Supplemental New Drug Application Planned for Submissi
Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients Supplemental New Drug Application Planned for Submission in Q1 2021 CAMBRIDGE, Mass., September 21, 2020 Agios P
Read more →AGIOAgios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 CAMBRIDGE, Mass., September 8, 2020 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field
Read more →AGIOAgios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Citi 15th Annual BioPharm
Read more →AGIOAgios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canaccord 40th Annual Gro
Read more →AGIOAgios Reports Business Highlights and Second Quarter 2020 Financial Results Second Quarter TIBSOVO Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO Net U.S. Revenue Guidance of $105 115 Million Significant C
Agios Reports Business Highlights and Second Quarter 2020 Financial Results Second Quarter TIBSOVO Net Revenue of $27.6 Million; Company TIBSOVO Net U.S. Revenue Guidance of Significant Clinical Progress for First-in-Class PKR Activator Mitapivat : Established Proof- of-Conce
Read more →AGIOAgios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020
CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, July
Read more →AGIOAgios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020
CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the BMO 2020 Prescriptions for Succes
Read more →AGIOAgios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA Royalty Royalty Pharma Acquires Rights to Agios Royalty on IDHIFA Worldwide Net Sales and Outstanding Regulatory Milestone Payments CAMBRIDGE,
Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA Royalty Pharma Acquires Rights to Agios Royalty on IDHIFA Worldwide Net Sales and Outstanding Regulatory Milestone Payments CAMBRIDGE, Mass. and NEW YORK, N.Y., June 12, 2020 Agios Pharmaceuticals, In
Read more →AGIOAgios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease
– 5 of 8 (63%) Efficacy Evaluable Patients Achieved a Hemoglobin Increase of ≥1.0 g/dL From Baseline – – Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with Pyruvate Kinase Deficiency or Expected in the Context of Sickle Cell Disease –
Read more →AGIOAgios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia
CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designa
Read more →AGIOAgios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity w
Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months Vorasidenib Demon
Read more →AGIOAgios Announces Publication of TIBSOVO Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
– TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma – CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat c
Read more →AGIOAgios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress
– Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation – – Agios to Host Investor Webcast on June 12 at 7:30 a.m. ET – CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular me
Read more →AGIOAgios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that vorasidenib and ivosidenib clinical data will be presented at the American So
Read more →AGIOAgios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the RBC Capital Markets Global Healthc
Read more →AGIOAgios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response First Quarter TIBSOVO Net Revenue of $22.7 Million; Company Reiterates 2020 TIBSOVO Net U.S. Revenue Gui
Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response TIBSOVO Net Revenue of $22.7 Million; Company Reiterates 2020 TIBSOVO Net U.S. Revenue Guidance of $105 115 Million New Clinical Data from Mitapivat in Thalassemi
Read more →AGIOAgios to Webcast Conference Call of First Quarter 2020 Financial Results on April 30, 2020
CAMBRIDGE, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, Apri
Read more →AGIOAgios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat in Pyruvate Kinase Deficiency
CAMBRIDGE, Mass., March 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Product
Read more →AGIOAgios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers Squibb
– Celgene Declines to Exercise Opt-in Right for MAT2A Inhibitor AG-270 – – Research Term of the Metabolic Immuno-oncology Collaboration to Conclude at the End of the Initial Four-year Period in May 2020 – – AG-270 Phase 1 Combination Expansion Trials Ongoing – CAMBRIDGE, Mass.
Read more →AGIOAgios Announces FDA Clearance of Investigational New Drug Application for AG-946, a Next-Generation PKR Activator
– Phase 1 Healthy Volunteers Study Expected to Begin in Mid-Year 2020 – CAMBRIDGE, Mass., March 23, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new
Read more →AGIOAgios to Present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020
CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Cowen 40th Annual Healthcare Conf
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2019 Financial Results Fourth Quarter TIBSOVO Net Revenue of $19.6M and $59.9M for Full Year 2019; Full Year 2020 U.S. TIBSOVO Net Revenue Expected to be Between $105-115 Millio
Agios Reports Fourth Quarter and Full Year 2019 Financial Results Fourth Quarter TIBSOVO Net Revenue of $19.6M and $59.9M for Full Year 2019; 2020 U.S. TIBSOVO Net Revenue Expected to be Between $105-115 Million New Clinical Data from Mitapivat in Thalassemia and Sickle Cell
Read more →AGIOAgios to Present at the Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020
CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Leerink 9th Annual Global Healthc
Read more →AGIOAgios to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, Febru
Read more →AGIOForward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forwar
AGIOS 2025 VISION 38th Annual J.P. Morgan Healthcare Conference January 13, 2020 Exhibit 99.1 Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litig
Read more →AGIOAgios Announces Agios 2025 Strategic Vision and Highlights 2020 Milestones In 2025, Company Expects to Have 4 Marketed Products in at Least 8 Indications, at Least 6 Molecules in Clinical Development and a Broad Research
Agios Announces Agios 2025 Strategic Vision and Highlights 2020 Milestones In 2025, Company Expects to Have 4 Marketed Products in at Least 8 Indications, at Least 6 Molecules in Clinical Development and a Broad Research Pipeline Broadening Opportunities for PKR Activation: To
Read more →AGIOAgios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020
CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the 38th Annual J.P. Morgan Healthcar
Read more →AGIOAgios Receives FDA Breakthrough Therapy Designation for TIBSOVO (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation
CAMBRIDGE, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy
Read more →AGIOAgios Presents Translational Data to Further Characterize the Role of TIBSOVO (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)
– Combination Therapy with TIBSOVO® and Azacitidine Results in Deep and Durable Molecular Remission in Newly Diagnosed IDH1 Mutant AML – – Mechanisms of Resistance and Relapse to Single Agent IDH1 Inhibitors Are Complex and Multiclonal and Include Both IDH-dependent and IDH-inde
Read more →AGIOAgios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency
– Robust Hemoglobin Increases Maintained in 18 Patients in the Extension Phase of the Study with Median Treatment Duration of Three Years – – Cumulative Safety Profile (Core Period plus Extension Phase) Continues to Support Long-term Twice Daily Dosing of Mitapivat – – Data fro
Read more →AGIOAgios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results Treatment with Mitapivat Induced Hemoglobin Increase of 1.0 g/dL in 7 of 8 Evaluable Patients
Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results Treatment with Mitapivat Induced Hemoglobin Increase of 1.0 g/dL in 7 of 8 Evaluable Patients Safety Profile Consistent with Previously Published Phase 2 Data for Mitap
Read more →AGIOAgios Appoints Bruce Car, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Bruce Car, Ph.D., as chief scientific officer effective Januar
Read more →AGIOAgios Appoints Jonathan Biller as Chief Legal Officer
CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Jonathan Biller to the newly created role of chief legal offic
Read more →AGIOAgios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma Preliminary Efficacy Data S
Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma Preliminary Efficacy Data Show 31% Overall Response Rate for Both Vorasidenib and TIB
Read more →AGIOAgios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an a
Read more →AGIOAgios Announces Pricing of $256 Million Public Offering of Common Stock
Agios Announces Pricing of $256 Million Public Offering of Common Stock CAMBRIDGE, Mass., November 7, 2019 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced that it has priced an underwritten public offering of 8,250,000 shares of common stock at a pri
Read more →AGIOAgios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting
– Important Translational Data for TIBSOVO® Underscore the High Clinical and Molecular Remissions Rate Observed in Combination with Azacitidine in IDH1 Mutant AML and Expand Understanding of Resistance Mechanisms – – Updated DRIVE PK Data for Mitapivat in PK Deficiency Patients
Read more →AGIOAgios Announces Proposed Offering of Common Stock
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced that it is offering to sell, subject to market and other conditions, up to 7.5 million shares of its common stock in an underwritten public offering. Agios also intends
Read more →AGIOAgios Reports Business Highlights and Third Quarter 2019 Financial Results TIBSOVO Net Revenue of $17.4 Million; 27% Growth from Q2 2019 Reported Positive Phase 3 ClarIDHy Results for TIBSOVO in Previously Treated IDH1 M
Agios Reports Business Highlights and Third Quarter 2019 Financial Results TIBSOVO Net Revenue of $17.4 Million; 27% Growth from Q2 2019 Reported Positive Phase 3 ClarIDHy Results for TIBSOVO in Previously Treated IDH1 Mutant Cholangiocarcinoma; sNDA Submission Planned by Year
Read more →AGIOAgios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP -Deleted Tumors Plasma SAM Biomarker Indicates Robust Target Engagement at Well Tolerated Dos
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors Plasma SAM Biomarker Indicates Robust Target Engagement at Well Tolerated Doses; AG-270 Maximum Tolerated Dose Determined to be 200 mg On
Read more →AGIOAgios to Webcast Conference Call of Third Quarter 2019 Financial Results on October 31, 2019
CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, Octob
Read more →AGIOAgios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference
CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the single agent dose-escalation portion of the ongoing Phase 1 study
Read more →AGIOData from Agios Phase 3 ClarIDHy Trial of TIBSOVO Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients TIBSOVO Reduced
Data from Agios Phase 3 ClarIDHy Trial of TIBSOVO Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients TIBSOVO Reduced the Risk of Disease Progression or Death by 63% (HR=0.37,
Read more →AGIOAgios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO
CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the Phase 3 ClarIDHy study of TIBSOVO® in previously treated IDH1 mu
Read more →AGIOAgios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine Maximum Hemoglobin Increases 1.0 g
Agios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine Increases >1.0 g/dL Observed in 50% of Patients in Core Period, Among Whom the Mean Maximum
Read more →AGIOAgios to Present at the Citi 14th Annual Biotech Conference on Thursday, September 5, 2019
CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Citi 14th Annual Biotech Conferen
Read more →AGIOAgios Reports Business Highlights and Second Quarter 2019 Financial Results Strong Topline Performance for IDH Inhibitors: TIBSOVO Net Revenue Increased 50% from Q1 2019 to $13.7M; IDHIFA Royalty Increased to $2.7M Achie
Agios Reports Business Highlights and Second Quarter 2019 Financial Results Strong Topline Performance for IDH Inhibitors: TIBSOVO Net Revenue Increased 50% from Q1 2019 to $13.7M; IDHIFA Royalty Increased to $2.7M Achieved Important Expansion Opportunities for TIBSOVO Includi
Read more →AGIOAgios to Webcast Conference Call of Second Quarter 2019 Financial Results on August 1, 2019
CAMBRIDGE, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, Augus
Read more →AGIOAgios Announces Orlando Oliveira Appointed as Senior Vice President and General Manager, International
CAMBRIDGE, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Orlando Oliveira to the role of senior vice president and gene
Read more →AGIOAgios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019
CAMBRIDGE, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Goldman Sachs Global Healthcare C
Read more →AGIOAgios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019
– Search Initiated for Company’s Next Chief Scientific Officer – – Dr. Biller to Remain a Strategic Advisor to Agios Through 2020 – CAMBRIDGE, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to tre
Read more →AGIOAgios Presents Updated Data from Phase 1 Studies of TIBSOVO (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy With Longer Follow Up, CR+C
Agios Presents Updated Data from Phase 1 Studies of TIBSOVO (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy With Longer Follow Up, CR+CRh Rate Increased to 70% and CR Rate Increased to 61% in t
Read more →AGIOAgios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients TIBSOVO Demonstrated a Statistically Significant I
Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant TIBSOVO Demonstrated a Statistically Significant Improvement in Progression-Free Survival Compared to Placebo Safety Profile Consisten
Read more →AGIOAgios to Present Clinical Data from its IDH Program at ASCO
CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that data from its isocitrate dehydrogenase (IDH) programs will be presented at th
Read more →AGIOAgios Reports Business Highlights and First Quarter 2019 Financial Results Commercial Organization Launch Ready Ahead of
Agios Reports Business Highlights and First Quarter 2019 Financial Results Commercial Organization Launch Ready Ahead of June 21, 2019 PDUFA Action Date for Single Agent TIBSOVO for IDH1m Newly Diagnosed AML Updated Data from Phase 1 Studies of TIBSOVO in Newly Diagnosed AML a
Read more →AGIOAgios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy TIBSOVO is the First and Only Therapy Approved for Newly
Read more →AGIOAgios to Webcast Conference Call of First Quarter 2019 Financial Results on May 2, 2019
CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, May
Read more →AGIOAgios Announces New Commercial Leadership Structure
Darrin Miles Appointed Senior Vice President, U.S. Commercial & Global Marketing; Previously Served as Vice President, Oncology Program Leadership at Agios Search Initiated for Senior Vice President, International to Lead the Build-Out of European Operations, Rest-of-World Strat
Read more →AGIOAgios Receives FDA Breakthrough Therapy Designation for TIBSOVO (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy
CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therap
Read more →AGIOAgios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Cowen 39th Annual Health Care Co
Read more →AGIOAgios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients
– Overall Response Rate of 78%, CR+CRh Rate of 65% and 12-month Survival Rate of 82% – – With Longer Follow Up Data, CR Rate Increased to 57% with Majority of Patients with CR Achieving IDH1 Mutation Clearance – – Mean Neutrophil and Platelet Counts Were Maintained Near or Abov
Read more →AGIOAgios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019
CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Leerink Global Healthcare Confere
Read more →AGIOAgios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy
CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s suppl
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2018 Financial Results
– Strong Launch of TIBSOVO® Continues with Net Revenue of $9.4M for the Fourth Quarter and $13.8M for Full Year 2018 – – Phase 3 ClarIDHy Trial of TIBSOVO® in Second Line or Later Cholangiocarcinoma Fully Enrolled – – AG-270 Preclinical Data Accepted for Presentation at AACR; D
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2018 Financial Results Strong Launch of TIBSOVO Continues with Net Revenue of $9.4M for the Fourth Quarter and $13.8M for Full Year 2018 Phase 3 ClarIDHy Trial of TIBSOVO in Sec
Agios Reports Fourth Quarter and Full Year 2018 Financial Results Strong Launch of TIBSOVO Continues with Net Revenue of $9.4M for the Fourth Quarter and $13.8M for Full Year 2018 Phase 3 ClarIDHy Trial of TIBSOVO in Second Line or Later Cholangiocarcinoma Fully Enrolled AG-
Read more →AGIOAgios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019
CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, Febru
Read more →AGIOAgios Highlights Key 2019 Initiatives to Broaden Potential for Late-Stage Cancer and Rare Genetic Disease Programs to Build Long-Term Value Expanding the Label for TIBSOVO : Supplemental New Drug Application (sNDA) Submi
Agios Highlights Key 2019 Initiatives to Broaden Potential for Late-Stage Cancer and Rare Genetic Disease Programs to Build Long-Term Value the Label for TIBSOVO : Supplemental New Drug Application (sNDA) Submitted for TIBSOVO as Monotherapy for Patients with Newly Diagnosed A
Read more →AGIOAgios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019
CAMBRIDGE, Mass., Dec. 28, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the 37th Annual J.P. Morgan Healthcar
Read more →AGIOAgios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)
– Single Agent Ivosidenib Demonstrated CR+CRh Rate of 42.4% and Overall Response Rate (ORR) of 57.6% in Newly Diagnosed AML Patients Ineligible for Standard Treatment – – Supplemental New Drug Application for Single Agent TIBSOVO® (ivosidenib) in Newly Diagnosed IDH1m AML Patien
Read more →AGIOAgios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation 91% CR+CRi/CRp Rate i
Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation 91% CR+CRi/CRp Rate in Ivosidenib-treated Patients with De Novo AML and 53% in
Read more →AGIOAgios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma Median Treatment Duration of 15 Months Observed in Non-Enhancing Glioma with 13 Patients Remai
Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma Duration of 15 Months Observed in Non-Enhancing Glioma with 13 Patients Remaining on Treatment Provides Evidence of Prolonged Disease Control Favorable
Read more →AGIOAgios Reports Third Quarter 2018 Financial Results Supplemental New Drug Application Submission for Single Agent TIBSOVO (ivosidenib) in Newly Diagnosed IDH1m AML Patients Not Eligible for Standard Treatment Planned by t
Agios Reports Third Quarter 2018 Financial Results Supplemental New Drug Application Submission for Single Agent TIBSOVO (ivosidenib) in Newly Diagnosed IDH1m AML Patients Not Eligible for Standard Treatment Planned by the End of January 2019 Enrollment for Phase 3 AGILE Trial
Read more →AGIOAgios to Present Updated Clinical Data at the 2018 ASH Annual Meeting
– Updated Single Agent Ivosidenib Data in Previously Untreated Acute Myeloid Leukemia (AML) Patients from Phase 1 Study Chosen for Oral Presentation – – Updated Data from Phase 1 Frontline AML Combination Study of Ivosidenib or Enasidenib and Intensive Chemotherapy Chosen for Or
Read more →AGIOAgios to Webcast Conference Call of Third Quarter 2018 Financial Results on November 1, 2018
CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, Novem
Read more →AGIOAgios Announces Chief Executive Officer Succession Plan - David Schenkein, M.D., Agios Long-Time Chief Executive Officer, to Become Executive Chairman, Effective
Agios Announces Chief Executive Officer Succession Plan - David Schenkein, M.D., Agios Long-Time Chief Executive Officer, to Become Executive Chairman, Effective February 1, 2019 - - Jacqualyn Fouse, Ph.D., to Succeed Dr. Schenkein as Chief Executive Officer - CAMBRIDGE, Mass.
Read more →AGIOAgios to Present at the Citi 13th Annual Biotech Conference Wednesday, September 5, 2018
CAMBRIDGE, Mass, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Citi 13th Annual Biotech Conferenc
Read more →AGIOAgios Reports Second Quarter 2018 Financial Results TIBSOVO Launch Underway Post FDA Approval for IDH1m R/R AML; Second Medicine Approved from Agios Discovery Platform in 12 Months Entered License Agreement with CStone P
Agios Reports Second Quarter 2018 Financial Results TIBSOVO Launch Underway Post FDA Approval for IDH1m R/R AML; Second Medicine Approved from Agios Discovery Platform in 12 Months Entered License Agreement with CStone Pharmaceuticals to Develop and Commercialize Ivosidenib i
Read more →AGIOAgios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, August
Read more →AGIOFDA Grants Approval of TIBSOVO , the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation - Approval of TIBSOVO was Based on Phase 1 Study Results, Includin
FDA Grants Approval of TIBSOVO , the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation - Approval of TIBSOVO was Based on Phase 1 Study Results, Including Rate and Duration of Complete Remission (CR) and CR wi
Read more →AGIOAgios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China - Agios to Receive $12 Million Upfront Payment and is Eligible to Receive D
Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China - Agios to Receive $12 Million Upfront Payment and is Eligible to Receive Development, Regulatory, and Sales-Based Milestones and Tie
Read more →AGIOAgios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
CAMBRIDGE, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the initiation of the Phase 3 ACTIVATE trial evaluating AG-348, a first-in-class,
Read more →AGIOAgios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors - Favorable Safety Profile at Dose Levels Below 100 mg; 10 mg and 50 mg Doses U
Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors - Favorable Safety Profile at Dose Levels Below 100 mg; 10 mg and 50 mg Doses Under Evaluation in Recently Initiated Glioma Perioperati
Read more →AGIOAgios to Present New Clinical Data from its IDH Programs at ASCO
– Updated Data From Ivosidenib Phase 1 Expansion in IDH1m R/R AML and the First Data from the AG-881 Phase 1 Study in IDHm Glioma to be Highlighted in Oral Presentations – – New Data From Fully Enrolled Ivosidenib Arm of the Phase 1/2 Combination Trial of Enasidenib or Ivosideni
Read more →AGIOAgios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day Commercial Infras
Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day Infrastructure In Place Ahead of August 21, 2018 PDUFA Action Date for TIBS
Read more →AGIOAgios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018
CAMBRIDGE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations from its Investor Day, including fir
Read more →AGIOAgios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018
CAMBRIDGE, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations from its Investor Day on Friday, May
Read more →AGIOAgios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced dosing of the first patient in a Phase 1 study of AG-270, a first-in-class methi
Read more →AGIOAgios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018
CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Cowen 38th Annual Healthcare Con
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2017 Financial Results All 2017 Key Milestones Achieved, Including First U.S. Product Approval from Agios Discovery Platform and NDA Submission for Second Product Candidate, Ivo
Agios Reports Fourth Quarter and Full Year 2017 Financial Results All 2017 Key Milestones Achieved, Including First U.S. Product Approval from Agios Discovery Platform and NDA Submission for Second Product Candidate, Ivosidenib, for 2018 Priorities Focus on Expanding Clinical
Read more →AGIOAgios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018
CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Wednesday, Febru
Read more →AGIOAgios Announces Pricing of $475 Million Public Offering of Common Stock
Agios Announces Pricing of $475 Million Public Offering of Common Stock CAMBRIDGE, Mass., Jan. 18, 2018 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced that it has priced an underwritten public offering of 7,089,553 shares of common stock at a price
Read more →AGIOAgios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value - Ivosidenib NDA for IDH1m R/R AML Submitted in December for Priority Review; Multiple Pivotal Trials Ongoing or Planne
Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value - Ivosidenib NDA for IDH1m R/R AML Submitted in December for Priority Review; Multiple Pivotal Trials Ongoing or Planned for Ivosidenib in Frontline AML and Solid Tumors Includi
Read more →AGIOAgios to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018
CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present at the 36th Annual J.P. Morgan Healthcare Con
Read more →AGIOAgios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation
- Ivosidenib Has Potential to be a First-in-Class Therapy for Patients with R/R AML and an IDH1 mutation - - Company Also Announces FDA Clearance of Investigational New Drug Application (IND) for AG-270 Targeting MTAP-Deleted Tumors; Phase 1 Study to Initiate in First Quarter 20
Read more →AGIOAgios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency Safety and E
Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency Safety and Efficacy Profile Consistent with Previously Reported Data
Read more →AGIOAgios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors
CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Jacqualyn “Jackie” Fouse, Ph.D., to its board of directors. “
Read more →AGIOAgios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma - Durable Stable Disease and Reduction of Tumor Growth Rates Observed for Patients with L
Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma - Durable Stable Disease and Reduction of Tumor Growth Rates Observed for Patients with Low Grade Glioma; Median Treatment Duration of 16 Months wi
Read more →AGIOAgios Reports Third Quarter 2017 Financial Results - IDHIFA Approval for IDH2m R/R AML Validates Precision Medicine Approach; Ivosidenib NDA Submission for IDH1m R/R AML on Track for Year End 2017 - First Expansion Data
Agios Reports Third Quarter 2017 Financial Results - IDHIFA Approval for IDH2m R/R AML Validates Precision Medicine Approach; Ivosidenib NDA Submission for IDH1m R/R AML on Track for Year End 2017 - First Expansion Data from Ivosidenib Phase 1 Trial in IDH1m R/R AML and First
Read more →AGIOAgios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual Meeting
– First Data From Ivosidenib Phase 1 Expansion in R/R AML and Phase 1 Frontline AML Combination Studies to be Highlighted in Oral Presentations – – Company to Host Investor Event and Webcast on December 11, 2017 – CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Agios Pharma
Read more →AGIOAgios to Present at the 26th Annual Credit Suisse Healthcare Conference Tuesday, November 7, 2017
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the 26th Annual Credit Suisse Healthc
Read more →AGIOAgios to Webcast Conference Call of Third Quarter 2017 Financial Results on November 1, 2017
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Wednesday, Novem
Read more →AGIOAgios to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Monday, September 11, 2017
CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Morgan Stanley 15th Annual Globa
Read more →AGIOAgios Reports Second Quarter 2017 Financial Results IDHIFA (enasidenib) Granted Approval from FDA as First Targeted Therapy for Patients with IDH2m R/R AML and First Product Approved from Agios Discovery Platform Trial D
Agios Reports Second Quarter 2017 Financial Results IDHIFA (enasidenib) Granted Approval from FDA as First Targeted Therapy for with IDH2m R/R AML and First Product Approved from Agios Discovery Platform Trial Designs Finalized for Two Pivotal Studies for AG-348 in Pyruvate Ki
Read more →AGIOAgios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017
CAMBRIDGE, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Canaccord Genuity 37th Annual Gro
Read more →AGIOFDA GRANTS APPROVAL OF IDHIFA , THE FIRST ORAL TARGETED THERAPY FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND AN IDH2 MUTATION IDHIFA is the first and only oral, targeted inhibitor of IDH2 1 FDA
FDA GRANTS APPROVAL OF IDHIFA , THE FIRST ORAL TARGETED THERAPY FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND AN IDH2 MUTATION IDHIFA is the first and only oral, targeted inhibitor of IDH21 FDA approval of IDHIFA was based on results from the phase I
Read more →AGIOAgios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017
CAMBRIDGE, Mass., July 28, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, August
Read more →AGIOAgios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348 s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency AG-348 Is Well-Tolerated and Demonstr
Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348 s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency AG-348 Is Well-Tolerated and Demonstrates Clinically Relevant, Rapid and Sustained Hemoglobin I
Read more →AGIOAgios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma - Durable Disease Control with Six Month PFS rate
Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Durable Disease Control with Six Month PFS rate of 38.5% and 12 Month PFS Rate of 20.7%; Median PFS of 3.8 Months - Disease Ob
Read more →AGIOAgios Appoints David Scadden, M.D., to the Board of Directors
CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic diseases, today announced the appointment of David Scadden, M.D., to its board of directors. Dr. Scadden is the Gerald and Da
Read more →AGIOAgios to Present Updated Clinical Data from PKR Activator AG-348 at EHA
CAMBRIDGE, Mass., May 18, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic diseases, today announced that updated clinical data from the fully enrolled, ongoing Phase 2 study (DRIVE PK) of AG-348 in a
Read more →AGIOAgios Reports First Quarter 2017 Financial Results IDHIFA (enasidenib) Granted Priority Review by FDA with
Agios Reports First Quarter 2017 Financial Results IDHIFA (enasidenib) Granted Priority Review by FDA with August 30, 2017 PDUFA Date; Updated Data from Phase 1/2 Trial in IDH2m R/R AML to be Presented at ASCO Ivosidenib Phase 1 125-Patient Expansion Cohort in IDH1m R/R AML Fu
Read more →AGIOAgios Announces Closing of Over-Allotment Option in Public Offering
CAMBRIDGE, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has issued an additional 757,575 shares of common stock at the public offering price of $49.50 per share, for total gross proceeds of approximately $37 million,
Read more →AGIOAgios to Webcast Conference Call of First Quarter 2017 Financial Results on May 4, 2017
CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, May 4
Read more →AGIOAgios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target
CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and Aurigene Discovery Technologies Limited today announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metaboli
Read more →AGIOAgios Announces Exercise of Over-Allotment Option in Public Offering
CAMBRIDGE, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that the underwriters of its previously announced public offering of common stock have fully exercised their option to purchase an additional 757,575 shares at the publi
Read more →AGIOAgios Announces Closing of Public Offering
CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of 5,050,505 shares common stock at the public offering price of $49.50 per share, resulting in gros
Read more →AGIOAgios Announces Pricing of $250 Million Public Offering of Common Stock
Agios Announces Pricing of $250 Million Public Offering of Common Stock CAMBRIDGE, Mass., April 18, 2017 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced that it has priced an underwritten a public offering of 5,050,505 shares of common stock at a pri
Read more →AGIOAgios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017
CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present at the 16th Annual Needham Healthcare Confer
Read more →AGIOAgios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene - Investigational New Drug (IND) Submission Expected by Year E
Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene - Investigational New Drug (IND) Submission Expected by Year End 2017 - CAMBRIDGE, Mass., March 13, 2017 Agios Pharmace
Read more →AGIOAgios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present at the Cowen and Company 37th Annual Health C
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones - Ivosidenib (AG-120) NDA Submission for IDH1m R/R AML Planned by Year End 2017; First Phase 1 Expansion Data Expected
Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones - Ivosidenib (AG-120) NDA Submission for IDH1m R/R AML Planned by Year End 2017; First Phase 1 Expansion Data Expected in the Second Half of - AG-348 Pivotal Trial Design Updat
Read more →AGIOAgios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017
CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, Februa
Read more →AGIOAgios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017
- Enasidenib (AG-221) NDA Submitted for IDH2m Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - - AG-120 NDA Submission for IDH1m R/R AML Planned by Year End 2017 - - AG-348 Advancing to Pivotal Development in PK Deficiency - - Development Candidate for MTAP Pathway Sel
Read more →AGIOAgios Appoints Ian Clark to Board of Directors
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the appointment of Ian Clark to its board of directors. Most recently, Mr. Clark served
Read more →AGIOAgios to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the company is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conferenc
Read more →AGIOAgios Provides Update on PKR Program
- Development of Second PKR Activator AG-519 Discontinued Following FDA Feedback - - Lead PKR Activator AG-348 Advancing into Pivotal Development in Pyruvate Kinase Deficiency - - Company to Host Conference Call and Webcast Today at 5:00 p.m. ET - CAMBRIDGE, Mass., Dec. 15, 20
Read more →AGIOAgios Provides Update on PKR Program - Development of Second PKR Activator AG-519 Discontinued Following FDA Feedback - - Lead PKR Activator AG-348 Advancing into Pivotal Development in Pyruvate Kinase Deficiency - - Com
Agios Provides Update on PKR Program - Development of Second PKR Activator AG-519 Discontinued Following FDA Feedback - - Lead PKR Activator AG-348 Advancing into Pivotal Development in Pyruvate Kinase Deficiency - - Company to Host Conference Call and Webcast Today at 5:00 p.
Read more →AGIOAgios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies
- Overall Response Rate of 38% and Complete Remission Rate of 18% with Patients on Study up to 24.2 Months - - For Relapsed/Refractory Acute Myeloid Leukemia Patients, Overall Response Rate of 33% and Complete Remission Rate of 16% with 6.5 Month Median Duration of Response - -
Read more →AGIOAgios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency - AG-348 Is Well-Tolerated and Demonstrates Clinically Relevant, Rapid and Sus
Agios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency - AG-348 Is Well-Tolerated and Demonstrates Clinically Relevant, Rapid and Sustained Hemoglobin Increases in 15 of 26 Patients with at L
Read more →AGIOAgios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma - Durable Stable Disease Observed for Patients with Non-enhancing Low Grade Glioma and Ch
Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma - Durable Stable Disease Observed for Patients with Non-enhancing Low Grade Glioma and Chondrosarcoma Patients; 42% of Glioma Patients Still on Tr
Read more →AGIOAgios to Present New Data from PKR and IDH Programs at the 2016 ASH Annual Meeting
- Updated Safety and Efficacy Data from AG-348, AG-519 and Completed Dose Escalation Portion of AG-120 Study to be Highlighted in Oral and Poster Presentations - - Company to Host Investor Event and Webcast on December 4, 2016 - CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE)
Read more →AGIOAgios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Programs Enasidenib (AG-221) on Track for NDA Submission in IDH2m Positive Relapsed/Refractory AML by Year End Fol
Agios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Enasidenib (AG-221) on Track for NDA Submission in IDH2m Positive Relapsed/Refractory AML by Year End Follow-on Offering Raised Approximately $173 Million in September; Upd
Read more →AGIOAgios to Present at the 25th Annual Credit Suisse Healthcare Conference Tuesday, November 8, 2016
CAMBRIDGE, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the 25th Annual Credit Suisse Healthcare Co
Read more →AGIOAgios to Webcast Conference Call of Third Quarter 2016 Financial Results on November 3, 2016
CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, November 3,
Read more →AGIOAgios Announces Pricing of $150 Million Public Offering of Common Stock
Agios Announces Pricing of $150 Million Public Offering of Common Stock CAMBRIDGE, Mass., September 14, 2016 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced that it has priced an underwritten public offering of 3,370,786 shares of common stock at a p
Read more →AGIOAgios to Present at Morgan Stanley Global Healthcare Conference Tuesday, September 13, 2016
CAMBRIDGE, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Morgan Stanley Global Healthcare Confe
Read more →AGIOAgios Appoints Andrew Hirsch as Chief Financial Officer CAMBRIDGE, MA.
Agios Appoints Andrew Hirsch as Chief Financial Officer CAMBRIDGE, MA., August 16, 2016 Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that Andrew Hirsch is joining the company as chi
Read more →AGIOAgios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016
CAMBRIDGE, Mass., Aug. 05, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Canaccord Genuity 36th Annual Growth Co
Read more →AGIOAgios Reports Second Quarter 2016 Financial Results - Data from PKR Activators at EHA Demonstrated Proof-of-Concept for AG-348 and Proof-of-Mechanism for AG-519; Program Moving Toward Pivotal Development in PK Deficiency
Agios Reports Second Quarter 2016 Financial Results - Data from PKR Activators at EHA Demonstrated Proof-of-Concept for AG-348 and Proof-of-Mechanism for AG-519; Program Moving Toward Pivotal Development in PK Deficiency with Molecule Selection by Year-End 2016 - - $200 Millio
Read more →AGIOAgios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
CAMBRIDGE, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 20
Read more →AGIOAgios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers - Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing - - Robust Dose-Dependent Changes in ATP and 2,3-DPG Blood Leve
Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers - Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing - - Robust Dose-Dependent Changes in ATP and 2,3-DPG Blood Levels Observed Consistent with PKR Enzyme Activation - - Com
Read more →AGIOAgios to Host Conference Call from the 21st Congress of the European Hematology Association
CAMBRIDGE, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 201
Read more →AGIOAgios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association
Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study Company to Host Conference Call and Webcast on Saturday, June 11, 2016 CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NAS
Read more →AGIOAgios Updates 2016 Financial Guidance
- $200 Million Upfront Payment from Celgene for New Metabolic Immuno-Oncology Collaboration - - Agios Expects 2016 Ending Cash Position of More than $390 Million - - Investor Conference Call Today at 5 p.m. ET - CAMBRIDGE, Mass., May 17, 2016 (GLOBE NEWSWIRE) -- Agios Pharmace
Read more →AGIOAgios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement - New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to R
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement - New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment - - AG-120 Rights Ou
Read more →AGIOAgios Reports First Quarter 2016 Financial Results - Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer
Agios Reports First Quarter 2016 Financial Results - Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study - - Enrollment Complete in AG-221 Phase 2 Expansio
Read more →AGIOAgios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016
CAMBRIDGE, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, May 5, 2016 a
Read more →AGIOAgios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy
CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1/2, multicenter, international, open-label study, sponsored
Read more →AGIOAgios to Present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8
CAMBRIDGE, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the company is scheduled to present at the Cowen and Company 36th Annual Health Care C
Read more →AGIOAgios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones - First Data from Phase 2 DRIVE PK Study for AG-348 in PK Deficiency and Phase 1 Healthy Volunteer Study for AG-519 to
Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones - First Data from Phase 2 DRIVE PK Study for AG-348 in PK Deficiency and Phase 1 Healthy Volunteer Study for AG-519 to be Submitted for Presentation at EHA - - Late-stage AG-2
Read more →AGIOAgios to Webcast Conference Call of Fourth Quarter and Full Year 2015 Financial Results on February 18, 2016
CAMBRIDGE, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, February 18,
Read more →AGIOAgios Appoints Steve Hoerter as Chief Commercial Officer
Agios Appoints Steve Hoerter as Chief Commercial Officer CAMBRIDGE, Mass., February 8, 2016 Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the appointment of Steve Hoerter to the newly
Read more →AGIOAgios to Present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10
CAMBRIDGE, Mass., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the company is scheduled to present at the Leerink Partners 5th Annual Global Healthcar
Read more →AGIOAgios Outlines Key 2016 Goals and Priorities
- Complete Enrollment of 125-Patient Expansion Cohorts for AG-221 and AG-120 in Relapsed/Refractory Acute Myeloid Leukemia in Second Half of 2016 - - Present First Data from Phase 2 DRIVE PK Study for AG-348 in PK Deficiency and Phase 1 Healthy Volunteer Study for AG-519 in Firs
Read more →AGIOAgios in 2016 JPMorgan Healthcare Conference
JPMorgan Healthcare Conference 2016 David Schenkein, M.D. Chief Executive Officer Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements of Agios Pharmaceuticals, Inc. within the mean
Read more →AGIOAgios to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11
CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the company is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conferenc
Read more →AGIOAgios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients
CAMBRIDGE, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1b, multicenter, international, open-label study of AG-221 or
Read more →AGIOAgios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies - Patients on Study for up to 14.1 Months with a Median Response Duration of 5.6 Mont
Agios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies - Patients on Study for up to 14.1 Months with a Median Response Duration of 5.6 Months - - Four Phase 1 Expansion Cohorts Enrolling; Planned
Read more →AGIOAgios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies
- Patients on Study for up to 18 Months with a Median Response Duration of 6.9 Months in Relapsed/Refractory Acute Myeloid Leukemia (AML) - - Enrollment Complete for Four 25-Patient Expansion Cohorts; 125-Patient Expansion Cohort and Phase 3 IDHENTIFY Study Open for Enrollment -
Read more →AGIOAgios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies
- Patients on Study for up to 14.1 Months with a Median Response Duration of 5.6 Months - - Four Phase 1 Expansion Cohorts Enrolling; Planned Global Registration-enabling Phase 3 Study On Track - - Company to Host Investor Event and Webcast Monday, December 7, 2015 - CAMBRIDGE
Read more →AGIOAgios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors - Safety Profile Confirmed; Signs of Clinical and Biological Activity Observed; Recommended Ph
Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors - Safety Profile Confirmed; Signs of Clinical and Biological Activity Observed; Recommended Phase 2 Dose - Phase 1 Expansion Cohorts for Patients with
Read more →AGIOAgios Reports Third Quarter 2015 Financial Results New AG-221 and AG-120 Data in Solid Tumors and Hematologic Malignancies to be Presented at AACR-NCI-EORTC and ASH Annual Meeting R&D Day Highlights Included Initiation o
Agios Reports Third Quarter 2015 Financial Results New AG-221 and AG-120 Data in Solid Tumors and Hematologic Malignancies to be Presented at AACR-NCI-EORTC and ASH Annual Meeting R&D Day Highlights Included Initiation of AG-221 Phase 3 IDHENTIFY Study, Design of AG-221 and AG-
Read more →AGIOAgios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting
- New Safety and Efficacy Data from Ongoing Studies of AG-221 and AG-120 to be Highlighted in Oral and Poster Presentations - - Posters to Feature Pharmacokinetics and Pharmacodynamics Data for AG-348 and Findings from Natural History Study of Pyruvate Kinase Deficiency - - Com
Read more →AGIOAgios to Present at Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10
CAMBRIDGE, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Credit Suisse 24th Annual Healthcare Conferenc
Read more →AGIOAgios to Webcast Conference Call of Third Quarter 2015 Financial Results on November 5, 2015
CAMBRIDGE, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, November 5,
Read more →AGIOAgios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC
CAMBRIDGE, Mass., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the first results from the Phase 1 study of AG-120 in patients with IDH1-mutant positive
Read more →AGIOAgios Outlines Key Clinical Development & Research Strategies
- Phase 3 Study of AG-221 in Relapsed/Refractory IDH2 Mutant Acute Myeloid Leukemia (IDHENTIFY) Initiated - - Frontline Combination Development Strategy for AG-221 and AG-120 Announced - - Second Pyruvate Kinase-R Activator AG-519 Entering Clinical Development - - Company to W
Read more →AGIOWhat s Possible at Agios
What s Possible at Agios David Schenkein, M.D. Chief Executive Officer Cautionary Note Regarding Forward-Looking Statements This 2015 Research & Development Day presentation and various remarks we make during this presentation contain forward-looking statements of Agios Pharm
Read more →AGIOAgios to Webcast R&D Day on October 16, 2015
CAMBRIDGE, Mass., Oct. 8, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will webcast presentations from its Research and Development (R&D) Day
Read more →AGIOAgios to Present at Leerink Partners Rare Disease Roundtable
CAMBRIDGE, Mass., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Leerink Partners 4th Annual Rare Disease Rou
Read more →AGIOAgios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress Global Phase 3 Registration-enabling Studies on Track to Begin in Second Half of 2015 for AG-221 & First Half of 2
Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress Global Phase 3 Registration-enabling Studies on Track to Begin in Second Half of 2015 for AG-221 & First Half of 2016 for AG-120 Phase 1 Expansion Studies for AG-221 & AG-
Read more →AGIOAgios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015
CAMBRIDGE, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company is scheduled to present at the Canaccord Genuity 35th Annual Growth Confe
Read more →AGIOAgios to Webcast Conference Call of Second Quarter 2015 Financial Results on August 6, 2015
CAMBRIDGE, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will host a conference call and live webcast on Thursday, August 6
Read more →AGIOAgios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation
- Third IDH Mutant Inhibitor to Enter Clinical Trials - - Brain Penetration and Pan-IDHm Inhibition Broaden Development Options for IDH Mutant-Positive Cancers, Including Gliomas - - Second Phase 1 Study in Hematologic Malignancies on Track to Begin Dosing in Coming Weeks - CA
Read more →AGIOAgios Appoints Maykin Ho, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., June 23, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company's board of directors has appointed Maykin Ho, Ph.D., former partne
Read more →AGIOAgios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation
CAMBRIDGE, Mass., May 18, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation
Read more →AGIOAgios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120
AG-221: Ongoing Phase 1 study expanded by an additional 125 patients in selected AML (acute myeloid leukemia) populations AG-120: Ongoing Phase 1 hematologic malignancy study expanded by 175 patients in three cohorts, including 125 patients in a defined AML population EHA: Abst
Read more →AGIOAgios Pharmaceuticals Selects Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development
- Brain-penetrant, pan-IDH mutant inhibitor broadens pipeline for treatment of patients with IDH mutant positive cancers - New worldwide development and profit share collaboration for AG-881 entered into by Agios and Celgene - Expect to initiate clinical development for AG-881
Read more →AGIOAgios Pharmaceuticals to Webcast Conference Call of First Quarter 2015 Financial Results on May 7, 2015
CAMBRIDGE, Mass., April 28, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will host a conference call and live webcast on Thursday, May 7,
Read more →AGIOAgios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency
- PK deficiency is a severe and rare genetic disease with currently no approved or disease modifying treatments - CAMBRIDGE, Mass., March 24, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorder
Read more →AGIOAgios Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference on Monday, March 2
CAMBRIDGE, Mass., Feb. 20, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the company will webcast its corporate presentation from the Cowen and Company 35th
Read more →AGIOAgios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
CAMBRIDGE, Mass., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the fourth quarter and year ended Dece
Read more →AGIOAgios Pharmaceuticals to Webcast Conference Call of Fourth Quarter and Full Year 2014 Financial Results on February 17, 2015
CAMBRIDGE, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will host a conference call and live webcast on Tuesday, February
Read more →AGIOAgios Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11
CAMBRIDGE, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the company will webcast its corporate presentation from the 2015 Leerink Global Hea
Read more →AGIOAgios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration
CAMBRIDGE, Mass., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that its collaboration partner Celgene Corporation has agreed that it will exercise
Read more →AGIOAgios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12
CAMBRIDGE, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the company will webcast its corporate presentation from the 33rd Annual J.P. Morgan
Read more →AGIOAgios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
CAMBRIDGE, Mass., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an ad
Read more →AGIOAgios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 1,986,455 shares of common stock at a price to the public of $110.75 per share, before underwriting discounts, which
Read more →AGIOAgios Pharmaceuticals Announces Proposed Offering of Common Stock
CAMBRIDGE, Mass., Dec. 9, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $175 million of its common stock in an underwritten public offering. Agios also intends to grant
Read more →AGIOAgios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors
CAMBRIDGE, Mass., Dec. 9, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the addition of Kaye Foster-Cheek as an independent director to the company's board
Read more →AGIOAgios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency
AG-348 Achieved Proof-of-Mechanism Through Substantial Effects on Two Key Biomarkers of Pyruvate Kinase Activity and Pathway Activation Data Presented at ASH Support Initiation of a Phase 2 Trial in Patients with PK Deficiency in First Half 2015 Company to Host Investor Lunch
Read more →AGIOAgios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016
CAMBRIDGE, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that Celgene Corporation has elected to extend the period of its exclusivity for an
Read more →AGIOAgios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers Company Expects Global Registration Program to Begin for IDH2 inhibitor AG-221 in 2015 and IDH1 inhibitor AG-120 by early 2016 Agios A
Read more →AGIOAgios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)
-Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML - -Data Support Initiation of Multiple Expansion Cohorts in the First Half of 2015- CAMBRIDGE, Mass. and BARCELONA, Spain, Nov. 18, 2014 (GLOBE
Read more →AGIOAgios Pharmaceuticals Reports Third Quarter 2014 Financial Results
CAMBRIDGE, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2
Read more →AGIOAgios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation Poster Presentation to Reveal First Clinical Data for AG-348, a Potential Treatment for Pyruvate Kinase Deficiency Company to Host Investor Lunch and Webcast on Monday, December 8, 2014 CAMBRIDGE, Mass.,
Read more →AGIOAgios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
CAMBRIDGE, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that it will host a conference call and live webcast on Friday, November 7, 2014, a
Read more →AGIOAgios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation
CAMBRIDGE, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced
Read more →AGIOAgios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221
Once-Daily Oral Dose Selected From Ongoing Phase 1 Study of AG-221 in Hematologic Malignancies Data From AG-120 to be Presented at EORTC-NCI-AACR 2014; AG-221 and AG-348 Data to be Presented at 2014 American Society of Hematology Annual Meeting Company to Webcast R&D Day Today
Read more →AGIOAgios Pharmaceuticals to Webcast R&D Day on October 15, 2014
CAMBRIDGE, Mass., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will webcast presentations at its Research and Development (R&D) Da
Read more →AGIOAgios Pharmaceuticals to Present at the 2014 Leerink Partners Rare Disease Roundtable
CAMBRIDGE, Mass., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the company will webcast its presentation at the 2014 Leerink Partners Rare Diseas
Read more →AGIOAgios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation
CAMBRIDGE, Mass., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation
Read more →AGIOAgios Pharmaceuticals Reports Second Quarter 2014 Financial Results
- AG-221: Company on track to start four Phase 1 expansion cohorts in second half of 2014; abstract of additional Phase 1 data submitted to the 2014 ASH Annual Meeting - - AG-348: Phase 1 healthy volunteer studies met primary endpoints; abstract of Phase 1 data has been submitte
Read more →AGIOAgios Pharmaceuticals to Webcast Conference Call of Second Quarter 2014 Financial Results on August 7, 2014
CAMBRIDGE, Mass., July 28, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that it will host a conference call and live webcast on Thursday, August 7, 2014 at 8:30 a.m
Read more →AGIOAgios Pharmaceuticals, Inc. [AGIO] to Ring The NASDAQ Stock Market Opening Bell
ADVISORY, Nov. 22, 2013 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. [AGIO], a leader in the fields of cancer metabolism and inborn errors of metabolism, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, Dr. David Schenkein, CEO will ring the Openin
Read more →Competitive Position
How AGIO ranks across every disease it competes inCompetitive Position is a premium feature
See how AGIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial